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ABSTRACT 
 
PHYSIOLOGIC EFFECTS OF CYTOCHROME P450 3A ACTIVITY 
 
(Under the direction of Dr. Nobuyo Maeda) 
 
 
 The cytochrome P450 3A (CYP3A) subfamily of enzymes comprises isoforms 
that catalyze metabolism of foreign or “xenobiotic” chemicals that include most 
marketed pharmaceuticals. CYP3A activities are also critical in clearing and altering 
the bioactivities of many endogenous molecules. Research into CYP3As has 
focused primarily on their roles in drug metabolizing; much less attention has gone 
to physiologic effects of CYP3A activities. I review here established and 
hypothesized physiologic roles for CYP3A enzymes.  
I have specifically studied whether CYP3As modulate renal sodium transport 
and blood pressure. A single-nucleotide polymorphism (SNP; A6986G) in the 
CYP3A5 gene determines CYP3A5 apoprotein expression and enzyme activity. 
A6986G was shown to predict renal CYP3A expression and activity among human 
kidney samples mostly from Caucasians and to associate with blood pressure and 
renal function among African-Americans.  
Genotyping for A6986G and additional expression-determining CYP3A5 
SNPs (G14690A and 27131-32insT) was performed for a larger group of African-
Americans. I show that genotypes at these loci can be computationally resolved into 
iv 
functional haplotypes, which may improve the ability of CYP3A5 SNPs to predict 
blood pressure and other phenotypes.  
I used mouse kidney collecting duct cells to study effects of a product of 
CYP3A catalysis, 6β-hydroxycorticosterone. I show that 6β-hydroxycorticosterone 
inhibits activity and expression of 11β-hydroxysteroid dehydrogenase type 2, an 
enzyme that prevents glucocorticoids from inappropriately activating the 
mineralocorticoid receptor. 6β-hydroxycorticosterone also appears to antagonize 
mineralocorticoid receptor-mediated increases in expression of genes related to 
sodium transport. 
Wild-type mice that were injected with 6β-hydroxycorticosterone failed to 
demonstrate greater sodium-sensitivity of blood pressure than did mice injected with 
vehicle. Mouse models were made to express human CYP3A5. Mice bearing a 
CYP3A5 transgene exhibited slightly higher blood pressures than did wild-type mice, 
an effect that may be sodium-dependent.  
Finally, I performed a systematic review and meta-analysis of subsequent 
human studies of CYP3A5 genotype associations with blood pressure and 
hypertension. Considerable variability is apparent among these studies. Intriguing 
data emerge but summary statistics for suitable studies (primarily of healthy whites) 
show little evidence for significant association. I discuss the need for increased 
standardization among future studies and for greater inclusion of black subjects.
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CHAPTER I: GENERAL INTRODUCTION 
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SUMMARY 
CYP3A enzymes have established and possibly undefined roles in mammalian 
physiology in addition to their known functions as drug-metabolizing enzymes. 
CYP3A enzymes and associated transport proteins interact with physiologically 
important molecules. Genetic analyses suggest an evolutionary importance for 
human CYP3A isoforms. In this chapter, I review literature pertaining to CYP3A 
metabolism and physiology.  
Herein I advance hypotheses concerning possible mechanisms of CYP3A 
action upon renal control of electrolyte balance and blood pressure. I also propose 
studies to address these ideas. These studies include a number of approaches and 
materials: human subjects, cellular and animal models, computational genetics, and 
meta-analyses of pre-existing studies. The conclusion offered by these studies is 
that roles for CYP3A enzymes in physiology remain intriguing, if puzzling, and that 
future studies would benefit from refining hypotheses and experimental methods. 
  
INTRODUCTION 
Cytochrome P450 Taxonomy 
The cytochrome P450 (CYP) enzyme superfamily is an exceedingly diverse group 
with members found among organisms in every taxonomic kingdom (1). The CYPs 
are hemoproteins that have absorption maxima near 450 nm. CYP enzymes 
catalyze the oxidations and reductions of a wide array of substrates. CYPs are 
divided into roughly 237 numbered families on the basis of sequence homology: 
19 
family members share greater than 40% sequence similarity and subfamily members 
are more than 55% similar (2). Sixteen CYP families are found among mammals (3). 
In addition to their handling of endogenous molecules, members of the first 
three families are also known to metabolize exogenous, or xenobiotic, compounds- 
including therapeutic drugs (4). CYP1-3 proteins constitute the phase I drug-
metabolizing enzymes, which catalyze the functionalization of their substrates via 
reactions (e.g., hydroxylation and demethylation) that increase aqueous solubility or 
introduce attachment sites for bulkier moieties to be added by phase II enzymes. 
CYP proteins are expressed in the liver and throughout the gastrointestinal tract, 
where the bulk of first-pass drug metabolism occurs (5). The generally non-CYP 
phase II enzymes- including glutathione S-transferases, sulfotransferases, and N-
acetyltransferases- conjugate molecules to create products that are more soluble 
and more readily excreted by drug transporters (6). CYP activities may constitute a 
defense against foreign chemicals, but some have also been shown to generate 
harmful metabolites, such as those of benzo(a)pyrene and aflatoxin B1 (7). 
 
CYP3A enzymes 
The term “CYP3A” denotes family 3, subfamily A of the CYP superfamily. The 
CYP3A enzymes function in the endoplasmic reticulum and require an electron 
transport chain provided by NADPH-cytochrome P450 reductase (8). Among human 
CYP subfamilies, CYP3A is the most prominent- its members are the most highly 
expressed in the liver and intestines and they catalyze the metabolism of a 
tremendous variety of substrates, including more than half of currently marketed 
20 
drugs (9). The four human CYP3A isozymes, which are numbered 4, 5, 7, and 43, 
have extensively overlapping substrate specificities.  
A gene cluster on human chromosome 7q21-q22.1 encodes the CYP3A 
enzymes; interspersed between the active genes are CYP3A pseudogenes, dormant 
remnants of duplication events (2, 10, 11) (Figure I-1). At least 6 mouse homologs 
reside in a syngeneic locus on mouse chromosome 5 (4, 12). All active human 
CYP3A genes have 13 exons. The evolutionary emergence of the CYP3A subfamily 
predates that of vertebrates, as CYP3-like genes are found even among the pre-
vertebrate tunicates (13). CYP3A isoforms are expressed throughout the vertebrate 
subphylum (4, 14) and phylogenetic analyses predict that the common ancestor of 
all vertebrates bore a single CYP3A gene that evolved to generate modern CYP3A 
gene clusters in each species through species-specific gene-duplication and 
recombination events (14).  
 
 
FIGURE I-1. Human CYP3A locus 
 
 
The CYP3A metabolic unit 
CYP3A enzymes can be considered to belong to a basic metabolic unit that also 
includes the nuclear hormone receptors pregnane X receptor (PXR) and retinoid X 
receptor (RXR) and the efflux transporter P-glycoprotein (P-gp), or multidrug 
resistance 1 transporter (MDR1). Levels of CYP3A and P-gp mRNAs are induced by 
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PXR/RXR heterodimers that bind to PXR response elements in CYP3A and MDR1 
gene promoters (15, 16). PXR ligands include endogenous and xenobiotic 
compounds that are often CYP3A substrates and P-gp ligands (17). P-gp may alter 
the extent of CYP3A metabolism by pumping CYP3A substrates out of the cell, and 
CYP3A may control the activity of PXR and P-gp by metabolizing PXR/P-gp ligands 
into less avid products (18, 19). In summary, there is a homeostasis in this system 
that is controlled by interplay among its members. As will be discussed, the 
CYP3A/PXR/P-gp unit is at the nexus of a broad network of physiologic systems. 
 
CYP3A metabolism 
CYP3A enzymes participate in the oxidative, reductive, and peroxidative metabolism 
of a very diverse array of exogenous and endogenous substrates. Exogenous 
substrates include xenobiotic environmental chemicals, against which the CYP3A 
enzymes may form a line of defense. CYP3A enzymes metabolize a large number of 
therapeutic drugs and may be important in altering drug activity or in promoting drug 
clearance. Intriguing roles have emerged for CYP3A enzymes in endogenous 
processes such as steroidogenesis and steroid catabolism, lipid metabolism, and the 
processing of bile acids and vitamin D. 
 
Distribution of CYP3A expression 
Human CYP3A enzymes differ in their temporal and anatomic distributions. CYP3A7 
expression is seen in utero but subsides by late infancy in most individuals (20). The 
CYP3A43 enzyme is limited in the distribution and magnitude of its expression and it 
22 
has low catalytic activity for CYP3A substrates (21, 22). Adult hepatic and intestinal 
CYP3A activity thus mainly reflects the contributions of CYP3A4 and CYP3A5. 
CYP3A4 expression is variable but apparently universal: humans lacking 
CYP3A4 have yet to be identified. Genetic variations that may control the levels of 
CYP3A4 expression have been identified (23); the most studied of these is the 
CYP3A4*1B allele, reflecting an A-392G single-nucleotide polymorphism (SNP) in 
the CYP3A4 promoter that is associated with decreased CYP3A activity (24). In 
contrast to that of CYP3A4, CYP3A5 expression is clearly polymorphic- that is, it is 
absent from some people. Furthermore, the frequency of CYP3A5 deficiency varies 
from one population to the other (25). The major genetic causes of CYP3A5 
deficiency are discussed below. 
Among people who express CYP3A5, hepatic levels of CYP3A5 may be only 
25% that of CYP3A4. But the hepatic aggregate CYP3A activity of CYP3A5 
expressers may be exceed that of CYP3A5 non-expressers (25, 26). CYP3A4 and 5 
may be co-expressed in extra-gastrointestinal sites such as the placenta (27). But 
CYP3A5 is also found in sites where CYP3A4 appears to be absent or undetectable. 
CYP3A5 is the predominant and perhaps exclusive 3A isoform in the kidney (28-30), 
including proximal and distal tubules and collecting ducts (21, 31); adrenal zona 
glomerulosa (21, 31); bronchial and alveolar respiratory epithelia (32); and anterior 
pituitary gland (33). Extra-gastrointestinal CYP3A expression is unlikely to contribute 
significantly to overall drug metabolism but may modulate peripheral toxicities and 
physiologic effects of exogenous and endogenous molecules (34, 35).  
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It is possible then that variance in some systemic and local adult CYP3A 
phenotypes reflects CYP3A5 polymorphism. For instance, CYP3A5 genotype and 
renal CYP3A5 expression may be associated with risk of nephrotoxic side effects 
due to CYP3A-substrate calcineurin inhibitors (tacrolimus and cyclosporin) (36-38). 
There has also been a suggestion that CYP3A5- and not CYP3A4- genotype 
modifies risk of a particular chronic nephritis (Balkan endemic nephropathy) whose 
likely etiologic agents include pro-toxic chemicals (e.g., ochratoxin A) that are 
activated by CYP3A enzymes (39, 40). 
 
CYP3A5 Genetic Variance 
Early studies of primarily Caucasian subjects suggested that the population-level 
impact of CYP3A5 expression would be small because the vast majority of subjects 
were clear non-expressers (41-43). However, expression frequency is much higher 
in non-white populations and generally exceeds half among black groups. In every 
human population studied so far, CYP3A5 expression variation mainly reflects the 
effect of a SNP, A6986G, in the third CYP3A5 intron that distinguishes the full-
expresser allele (called *1) from a reduced-expresser allele (*3) (44). The A-to-G 
transition at this position functions as an alternative splice acceptor site that is 
preferred over the canonical exon 4 acceptor site; the frame-shifted variant mRNA 
predicts a truncated protein but the mRNA itself in unstable due to nonsense-
mediated decay (45, 46). Two additional CYP3A5 SNPs, G14690A and 27131-
32insT, respectively define the *6 and *7 alleles and are specific to black groups; the 
frequency of each allele is roughly 0.10 (25, 47). The *6 allele may cause splicing 
24 
defects that result in skipping of exon 7; the single-base insertion in exon 11 that 
defines *7 results in frame-shifted mRNA, a premature stop codon, and truncated 
protein (44, 45, 47). 
 
Ethnic differences in CYP3A5 allele frequencies 
The allelic frequency of CYP3A5*3- which is inversely proportional to the prevalence 
of CYP3A5 expression in a population- is roughly 0.27-0.30 among African-
Americans (47), 0.60 among Southeast Asians (48), 0.73-0.76 among Chinese and 
Japanese (48-50), and 0.88-0.96 among Caucasians (21, 22, 26, 47, 51, 52). 
Accordingly, CYP3A5 protein levels are below limits of detection for Western blot in 
the majority of liver samples from Caucasians but are found in most samples from 
African-Americans (25). The *6 and *7 alleles, which are found almost exclusively 
among black groups, occur at respective frequencies of roughly 0.15 and 0.10. A 
summary of *3, *6, and *7 allele frequencies is shown in TABLE I-A. Information 
about lower-frequency CYP3A5 SNPs may be found elsewhere (23). 
TABLE I-A. CYP3A5 allele frequencies among populations 
Allele Frequency 
Population 
*3 
(A6986G) 
*6 
(G14690A) 
*7 
(27131 insT) N Refs. 
Black      
     Afr.-American 0.27-0.30 0.13 0.10  (25, 47) 
     Gabonese 0.21 0.10 0.10 72 (53) 
     Nigerian 0.16 0.09 0.15 212  
     Seychelles 0.36 0.09 0.11 375 (54) 
     Zimbabwean 0.78 0.22 0.10 400 (55) 
      Asian      
     Chinese 0.76-0.78    (48, 56) 
     Japanese 0.76-0.77     (57, 58) 
     Malay 0.60    (48) 
      
25 
White      
     Canadian 0.93 0.00 0.00 312 (55) 
     British 0.94    (52) 
     Dutch 0.91 0.001   (51) 
     French 0.92   102 (53) 
     German 0.96    (22) 
     Spanish 0.91    (59) 
Multiethnic or 
undetermined      
     
     Tunisian 0.81 0.01 0.00 72 (53) 
 
 
The Physiologic Impacts of CYP3A Enzymes 
CYP3A enzymes play a critical role in the metabolism of bile acids. CYP3As belong 
to a minor pathway for the production of the primary bile acid cholate. CYP3A 
activity is the major route for clearance of the toxic secondary bile acid metabolite 
lithocholic acid (LCA). LCA is carcinogenic and may have a causative role in some 
cases of colon cancer. By preparing LCA for clearance, CYP3A enzymes limit its 
activation of prominent nuclear receptors such as farnesyl X receptor (FXR), the 
constitutive androstane receptor (CAR), and the vitamin D receptor.  
 
Oxysterol and lipid metabolism 
The biologically-stable oxysterol 4β-hydroxycholesterol is produced by CYP3A 
enzyme activity (60, 61). It is a ligand for liver X receptor α (LXRα) (62). LXRα and β 
are nuclear receptors that are critical players in lipoprotein metabolism, cholesterol 
efflux, and glucose utilization. LXR activation is generally considered to have 
beneficial effects on energy balance: increased HDL levels and reverse cholesterol 
transport and increased glucose tolerance (63). 
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Eicosanoids and renal function 
CYP3A enzymes are expressed in muscular arteries. In animal models, their 
production of epoxyeicosatrienoic acid (EET) metabolites of arachidonic acid 
appears to mediate potassium channel-dependent vasorelaxation (64-66). EETs 
modulate the effects of the epithelia sodium channel (ENaC) and angiotensin II on 
renal sodium excretion.  
 
Vitamin D, bone health, and cancer 
1α,25-dihydroxyvitamin D3 induces CYP3A expression (67, 68), and CYP3A 
enzymes can inactivate 1α,25-(OH)2D3 through 24-hydroxylation and can thus 
potentially affect bone health. CYP3A inducers such as phenobarbital, ifosfamide, 
rifampin, and anticonvulsants have known potentials for reducing 1α,25-(OH)2D3 
levels and causing rickets and osteomalacia (68-76). As mentioned, CYP3A 
enzymes inactivate LCA, a potent carcinogen that promotes its own detoxification 
through induction of CYP3A expression by activating the vitamin D receptor (VDR). 
Noted relationships between sunlight exposure and cancers of the colon, prostate, 
and breast (77) may reflect ultraviolet light activation of vitamin D, which enhances 
bile acid excretion (78), and the association of geographic latitude with CYP3A 
expression, discussed below. 
 
Steroid metabolism 
CYP3A enzymes exhibit broad specificity for steroids. The 3As have important roles 
in hydroxylation of testosterone (e.g., at the 2β, 6β, or 15β positions) and estrogen 
27 
(positions 4 and 16α) (79). It can be induced by various compounds including drugs, 
pesticides, and carcinogens, resulting in high CYP3A4 levels in liver and other 
tissues, including mammary. Oxidations of these steroids have incompletely defined 
effects on their bioactivities, but may be responsible for some of the associations 
between CYP3A activity and cancers of the prostate and breast. The particular 
reaction most pertinent to this review is 6β-hydroxylation (FIGURE I-2). 
 
FIGURE I-2. CYP3A enzymes catalyze steroid 6β-hydroxylation 
 
CYP3A-mediated 6β-hydroxylation is a metabolic pathway in vertebrates for steroids 
that include, in addition to androgens, the glucocorticoids cortisol and corticosterone, 
and the mineralocorticoid aldosterone. 6β-hydroxyglucocorticoid products of CYP3A-
catalyzed reactions stimulate sodium transport across A6 toad kidney cells and 
induce sodium retention and increased creatinine clearance in rats (80-82). 
CYP3A enzymes may modulate of A6 sodium transport through a 
mineralocorticoid receptor (MR)-mediated mechanism (83). Immunohistochemistry 
detects CYP3A proteins in rat kidney (80) and human distal tubules and collecting 
ducts (84), the principle sites at which corticosteroids stimulate sodium resorption. 
6β-hydroxysteroids have been postulated to exert mineralocorticoid-like renal effects 
28 
(80). The findings of these studies present some confusion, however, as 6β-
hydroxycortisol appears not to activate the MR but may antagonize it and appears 
not to act through the glucocorticoid receptor (GR). CYP3A activity, along with that 
of 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2), has been proposed to 
regulate glucocorticoid occupancy of MRs (83). 
Human and animal data suggest the potential clinical importance of excess 
CYP3A activity. Renal CYP3A content and catalytic activity in the spontaneously 
hypertensive rat (SHR) are higher than in the normotensive Wistar-Kyoto rat (80, 
85). Treatment of SHR with the CYP3A-selective inhibitor troleandomycin lowers BP 
(85). Several human diseases associated with elevated blood pressure, including 
Cushing’s syndrome (86) and pre-eclampsia (80), are characterized by increased 
urinary excretion of 6β-hydroxycortisol, a marker of in vivo CYP3A activity. A single 
study showed increased serum 6β-hydroxycortisol levels among essential 
hypertensives relative to normotensive individuals (87). Another demonstrated that a 
high-sodium diet caused an increase in urinary 6β-hydroxycortisol among sodium-
sensitive African-American subjects in contrast to a decrease among those who 
were sodium-resistant (88). But it is not known whether elevated 6β-hydroxycortisol 
levels in these conditions truly reflect an increase in CYP3A activity or merely a 
spillover of increased cortisol levels into the CYP3A pathway, or whether 6β-
hydroxysteroids play significant pathophysiologic roles in these diseases. 
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CYP3A5 and selective pressure 
CYP3A5 expression by latitude 
As discussed CYP3A5 expression is polymorphic. Why might CYP3A5 
polymorphism have arisen and what might explain interpopulation differences in 
CYP3A5 expression? Certainly, the impact of CYP3A enzymes on modern 
pharmacology cannot be invoked here. Implicit in CYP3A5*3 allelic frequency data is 
the possibility of systematically higher prevalences of CYP3A5 expression among 
populations that have historically lived near the equator than among those from 
higher latitudes; data by Thompson, et al. bear this out. Using samples from the 
Human Genome Diversity Panel-Centre d’Etude du Polymorphisme Humain (HGDP-
CEPH), these researchers show that CYP3A5*3 allele frequency correlates with 
latitude (Spearman’s ρ=0.612; P<0.0001) (89). It is possible that this relationship is 
due to genetic drift (i.e., to sheer chance), but the finding that CYP3A5*3 frequency 
correlation with latitude in this study exceeded those of 99% of microsatellite alleles 
at genome-wide loci may point toward more than chance association. An unusually 
low degree of haplotype diversity among non-African samples (Coriell Cell 
Repositories) was noted at the CYP3A gene cluster- especially at CYP3A5- which 
would be consistent with selection at this locus (89-91). 
 
Toxicologic pressure 
Why might CYP3A5 expression frequency have declined with increasing latitude? 
Hypothetically, some deleterious effects of CYP3A5 expression may have 
progressively outweighed its benefits as humans moved away from the equator. The 
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diversity of CYP3A substrates makes plausible a variety of hypotheses. Certainly, 
the central role of the CYP3A/PXR/MDR1 system in xenobiotic metabolism suggests 
that chemical threats may have exerted pressure upon CYP3A expression. CYP3A 
enzymes have a demonstrated role in the activation of promutagenic heterocyclic 
amines (92-94). The procarcinogenic and proteratogenic aflatoxin B1 (AFB1) 
produced by Aspergillus fungal species is also activated by CYP3A enzymes, and 
there is an apparent CYP3A5 expresser allele dose relationship among Africans with 
biomarkers of AFB1 activation (95-97).  
 
Sunlight and vitamin D 
The involvement of CYP3A enzymes in vitamin D metabolism reasonably suggests 
an ability of CYP3A5 to modify the physiologic effects of sunlight exposure. During 
childhood, vitamin D deficiency can cause a number of rachitic skeletal features, 
including a shallow pelvis, which could negatively affect reproductive fitness (98). 
High CYP3A activity might have become detrimental at progressively polar latitudes; 
decreasing CYP3A5 activity would then parallel the loss of melanin that may enable 
ultraviolet light to form cholecalciferol in people living toward the poles (99, 100). 
CYP3A-mediated decreases in vitamin D may have had a secondary effect upon 
blood pressure and renal sodium balance- vitamin D is a negative regulator of the 
renin-angiotensin-aldosterone system (discussed below) (101) and vitamin D levels 
are inversely associated with blood pressure and the risk of hypertension (102, 103); 
vitamin D levels may be decreased in pre-eclamptic women (104). Lastly, vitamin D 
controls activity of the insulin-like growth factor (IGF) system, an important 
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determinant of birth weight (105, 106). Thus, CYP3A activity may play important 
roles in the modulation of reproductive fitness by vitamin D. 
 
Heat stress and sodium 
Ideas about vitamin D and sunlight exposure parallel those concerning the impacts 
of heat and sodium demand on African emigrants and their descendants. The 
modern human (Homo sapiens sapiens) emerged on the African continent 140,000 
to 200,000 years ago, a figure based upon fossil records and mitochondrial DNA 
sequences (107, 108). The oldest known fossilized skeletons of modern humans to 
be found outside of the African continent- on the Arabian peninsula- date back to 
100,000 years ago (109). Into the warm and humid African climate of that era arose 
a relatively hairless group with a tremendous capacity to sweat that aided in 
evaporative cooling but also imposed a risk for large losses of water and of sodium, 
the most critical ionic regulator of mammalian osmosis and extracellular volume. 
Low sodium content of tropical soil may have added to the risk of volume depletion 
and dehydration (110). It is likely that, among these early humans, those who had an 
enhanced ability to retain sodium and water enjoyed a significant survival 
advantage. Retention of these abilities at less stressful altitudes might have harmed 
reproductive success, as demonstrated by the ability of antidiuretic hormone 
(vasopressin), normally produced in response to dehydration, to cause preterm 
pregnant uterine contractions (111). 
A role for CYP3A5 in the response to the threat of dehydration may be 
supported by the finding that human CYP3A expression, like that of aquaporin-2 
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(aqp2), increases in response to ambient hypertonicity. The promoters of the 
CYP3A4, 5, and 7 and aqp2 genes all contain tonicity-responsive enhancers (112). 
 
RAAS pathway 
Central to the physiological control of sodium and water balance is the renin-
angiotensin-aldosterone system (RAAS). Classically, the renal juxtaglomerular 
apparatus (JGA) responds to a decrease in blood pressure or in the rate of sodium 
delivery to the kidney by releasing renin, which cleaves hepatically-secreted AGT to 
produce the angiotensin I (AT-I). The angiotensin-converting enzyme (ACE), which 
is found primarily in pulmonary vascular beds, processes AT-I into angiotensin II 
(AT-II). AT-II has a number of functions that include vasoconstriction and increasing 
aldosterone synthesis and secretion by adrenal zona glomerulosa cells. Aldosterone 
secretion leads to increased renal sodium and water reabsorption (113). Resetting of 
sodium and volume homeostasis causes feedback inhibition of renin release, 
decreasing AT-II production. The RAAS system was likely critical for early human 
survival. But when salt availability is not limited, excess RAAS activity may be 
detrimental- it has been implicated, for instance, in pre-eclampsia (114). Balance 
between sodium avidity’s positive and negative effects might thus have shifted with 
heat stress and sodium demand. Accordingly, linkage disequilibrium (LD) patterns at 
the AGT gene locus are suggestive of directional selection on this gene that 
correlates with latitude (115). 
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CYP3A5 A6986G covariance with hypertension gene candidates 
The CYP3A5*3 allele (6986G), which is not physically linked to the AGT gene, may 
have faced similar pressures. In the study by Thompson, et al. the frequency of an 
AGT variant (M235) that predicts decreased plasma AGT levels correlated with 
latitude and with CYP3A5*3 frequency (Spearman ρ=0.712 and 0.680, respectively; 
both P<0.0001) (89). A separate group, led by Young, determined functional allele 
frequencies among the HGDP-CEPH panel for five HTN candidate genes and 
calculated standardized coefficients (β) for regression on absolute latitude. As 
shown in TABLE I-B, all but one allele were more strongly correlated with latitude 
than at least 96% of short tandem repeat markers (STRs) and control SNPs (116). 
Using data from Thompson, et al. (89), I calculated a β coefficient of -0.58 for 
CYP3A5 A6986 (P<0.0001), indicating that each 10° increase in absolute latitude is 
associated with a CYP3A5*3 allele frequency increase of 0.09; the strength of its 
association with latitude places it among these HTN candidates. 
 
TABLE I-B. Hypertension gene allele frequency associations with latitude 
Allele                          β 
AGT -6A -0.91 
GNB3 825T -0.79 
ENaCα -946G -0.59 
CYP3A5 A6986 -0.58 
ENaCγ -173G -0.47 
ADRB2 47A/79C -0.40 
AGT-217A 0.09 
STRs and control SNPs Mean: -0.03 
SD: 0.21 
Range: [-0.71, 0.71]  
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Direct interactions between CYP3A activity and the RAAS pathway have not 
been shown, but the CYP3A metabolic partner P-gp/MDR1 has been implicated in 
RAAS modulation. P-gp transports many CYP3A substrates- including aldosterone 
and cortisol (117, 118)- is expressed in the distal renal tubules and the adrenal 
cortex, and is an important component of the blood brain barrier in humans and in 
animal models (119-121). Subjects homozygous for an MDR1 reduced-expresser 
allele (3435T) gene show an exaggerated increase of serum aldosterone in 
response to angiotensin II infusion and fail to appropriately increase urinary sodium 
excretion in response to salt loading (122). 
There is reason to suspect that the prehistoric CYP3A5 expression modulated 
physiologic control of sodium balance (25, 44). But the truth of this contention is 
likely unknowable. With respect to its modern importance, the most obvious 
hypothetical harm of high CYP3A5 expression is a risk of high blood pressure- 
sodium avidity in the setting of a modern abundance of dietary salt might lead to 
hypervolemia and/or hypertension.  
Hypertension itself is a major continuous risk factor for disability and death 
related to disease of the coronary vessels and peripheral vasculature, 
cerebrovascular accidents, and renal disease. It is perhaps worth noting that not 
only are people of African descent the most frequent CYP3A5 expressers but also 
that African-Americans have the highest global rates of sodium sensitivity and HTN 
(123, 124). Both hypertensive and normotensive blacks demonstrate, on average, 
lower plasma renin levels than whites (125). This consistent finding may indicate a 
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decreased capacity for renal sodium excretion among African-Americans or an 
increased tendency toward sodium reabsorption by unidentified mechanisms. 
Potentially related to increased rates of hypertension among African-
Americans is a higher frequency of pregnancies that result in low-birth weight 
babies. A number of epidemiologic studies demonstrate an association between low 
birth weight or prematurity and the risk of adult hypertension. 
 
UNIFYING HYPOTHESIS 
Some of the effects of 6β-hydroxycorticosterone may mimic classic mineralocorticoid 
activity, but it appears to activate sodium flux primarily through a distinct non-
MR/non-GR A6 cell binding site (81). Subsequent studies suggest that such a 
binding site may be 11β-HSD2 (126, 127), an NADH-dependent enzyme that limits 
activation of MR by cortisol and corticosterone in aldosterone-sensitive epithelia by 
catalyzing their conversion to their respective 11-oxidized metabolites cortisone and 
11-dehydrocorticosterone, which are weaker agonists for MR (Figure I-3). 
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FIGURE I-3. 11β-HSD2 limits glucocorticoid transactivation of 
mineralocorticoid receptors 
 
Genetic 11β-HSD2 deficiency causes the syndrome of apparent mineralocorticoid 
excess (AME), so named because its features of hypertension and hypokalemia 
would suggest high aldosterone levels. To the contrary, aldosterone and renin levels 
in this condition are low, indicating a sodium-replete hypervolemia. Glycyrrhetinic 
acid derivatives such as carbenoxolone inhibit 11β-HSD2 and cause an AME-like 
pseudohyperaldosteronism. The existence of an 11β-HSD2 knockout mouse model 
that exhibits hypertension, hyporeninemia, and low birth weight reinforces the 
physiologic importance of the enzyme.  
It may be speculated that similarities between 11β-HSD2 deficiency and the 
syndromic presentation of sodium sensitivity, decreased plasma renin, and low birth 
weight among African-Americans as a group is suggestive of a possible role for 
reduced 11β-HSD2 in this phenomenon. I have hypothesized that CYP3A effects in 
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mineralocorticoid-sensitive tissues reflect 6β-hydroxysteroid inhibition of 11β-HSD2 
(FIGURE I-4). The significance of the proposed studies lies in their potential to 
legitimize or disprove a causative role for CYP3A activity in vertebrate renal 
physiology and to unmask possible molecular mechanisms underlying their effects. 
The gap in the literature that these studies may remedy is the demonstration that BP 
and other physiological effects can be specifically attributed to CYP3A activity and 
are not simply the result of association due to confounding. The particular promise of 
the CYP3A system lies not only in their possible etiologic role in HTN but also in 
their capacity to metabolize medications that include antihypertensives such as the 
calcium-channel blockers; thus, CYP3A activity may not only influence the 
susceptibility to HTN but also the response to some pharmacologic therapies. 
Because of this potential CYP3A “double effect”, this system may be a promising 
target for novel drug therapy. 
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FIGURE I-4. Proposed mechanism of 6β-hydroxysteroid effects on renal 
sodium transport. 
  
 
 
 
CHAPTER II: CYP3A5 GENOTYPE PREDICTS RENAL CYP3A ACTIVITY AND 
BLOOD PRESSURE IN HEALTHY ADULTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Chapter II contains material originally printed in J Appl Physiol 2003; 95:1297-1300. 
It is used with permission of the American Physiological Society.) 
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SUMMARY 
A single nucleotide polymorphism (SNP), A6986G, in the cytochrome P450 3A5 
(CYP3A5) gene distinguishes an expressor (*1) and a reduced-expressor (*3) allele 
and largely predicts hepatic and intestinal CYP3A5 content. CYP3A5 is the 
prevailing CYP3A isoform in the kidney, where CYP3A activity has been proposed to 
affect blood pressure (BP) by altering sodium transport. This chapter reports that 
among renal microsomes from 21 organ donors, those from *1/*3 individuals had at 
least 8-fold higher mean CYP3A5 content and 18-fold higher mean CYP3A catalytic 
activity than did microsomes from *3/*3 individuals (p=0.0001 and p=0.0137, 
respectively). Among a group of 25 healthy African-American adults, there were 
significant associations between the A6986G SNP and systolic BP (SBP; p=0.0007), 
mean arterial pressure (MAP; p=0.0075), and creatinine clearance (CrCl; p=0.0035). 
These associations remained significant when sex, age, and body mass index (BMI) 
were taken into account. The mean SBP of homozygous CYP3A5 expressors (*1/*1) 
exceeded that of homozygous non-expressors (*3/*3) by 19.3 mmHg. It is 
speculated whether a high CYP3A5 expressor allele frequency among African-
Americans may contribute to a high prevalence of sodium-sensitive hypertension in 
this population. 
 
INTRODUCTION 
Cytochrome P450 3A (CYP3A) homologs are variably expressed in human and rat 
liver (25, 128), kidney (28, 80), adrenal gland (21), and anterior pituitary gland (33). 
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The physiologic effects of CYP3A enzyme activity have not been clearly defined, but 
some observations support a role in the control of blood pressure (BP). CYP3A 
content and catalytic activity in the kidneys of spontaneously hypertensive rats 
(SHR) are higher than in normotensive Wistar-Kyoto rats (80, 85). Treatment of SHR 
with the CYP3A inhibitor troleandomycin lowers BP (85). Several human diseases 
associated with elevated BP, including Cushing’s syndrome (129) and pre-eclampsia 
(80), are characterized by increased urinary excretion of 6β-hydroxycortisol, a 
marker of in vivo CYP3A activity (85, 130). Plasma levels of 6β-hydroxycortisol have 
been reported to be elevated in essential hypertensives (87) 
A role for CYP3A enzymes in blood pressure control appears scientifically 
plausible. CYP3A-mediated 6β-hydroxylation is a minor metabolic pathway for 
steroids, including the glucocorticoids cortisol and corticosterone. 6β-hydroxysteroid 
products of CYP3A-catalyzed reactions stimulate sodium transport across A6 toad 
kidney cells and sodium retention in rats (80-82). Previous evidence indicates 6β-
hydroxycorticosterone modulation of A6 cell sodium transport by acting through an 
unidentified binding site (80, 81). Consistent with data from rat kidney (80, 131), 
immunostaining for CYP3A highlights human distal tubules and collecting ducts (84), 
the principle sites at which aldosterone stimulates sodium reabsorption. Renal 
CYP3A activity, along with that of 11β-hydroxysteroid dehydrogenase type 2, has 
been proposed to regulate glucocorticoid occupancy of the mineralocorticoid 
receptor (MR) (83). 
It has been established that, among all CYP3A isoforms, the expression of 
CYP3A5 prevails in the human kidney (28, 37). The discovery of genetic variants 
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underlying polymorphic CYP3A5 activity has made possible non-invasive studies of 
the contribution of polymorphic CYP3A5 expression to human renal CYP3A activity 
and blood pressure. CYP3A5 expression in liver (25) and intestine (26) is largely 
determined by the A6986G SNP that distinguishes the CYP3A5*1 (“expressor”) 
allele from the *3 (a “reduced-expressor”) allele. This study reports that A6986G 
predicts renal CYP3A5 activity among mostly Caucasian organ donors and BP and 
CrCl among a group of healthy young African-American adults. 
 
METHODS 
All studies were approved by the University of North Carolina (UNC) Committee on 
the Protection of Human Research Subjects. 
 
Renal microsome studies: CYP3A catalytic activity and CYP3A5 immunoreactivity 
were assayed in renal tissue samples from 21 organ donors- 17 were Caucasian, 
one was Hispanic, and three were of unknown ethnicity. All methods were described 
previously (26). CYP3A5 genotypes were determined by direct genomic DNA 
sequencing (see below). Microsomes were isolated by differential centrifugation. 
CYP3A5 content in 50 µg of microsomes was measured by Western blot with a 
CYP3A5-specific antibody (BD Gentest; Woburn, MA); undetectable bands were 
assigned a value of 0.25 pmol/mg, the limit of quantitation (LOQ; Figure 1A). 
Midazolam (MDZ) 1’-hydroxylation was measured after a 15-minute incubation of 
200 µg protein with 8 µM MDZ; microsomes with undetectable activity were given 
the LOQ value of 0.04 pmol/min/mg.  
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Human subjects: 89 unrelated self-identified healthy African-American volunteers 
between 18 and 65 years of age were genotyped for the CYP3A5 *3 allele using 
previously-described methods, as below (25). For all subjects, in-person informed 
consent was obtained.  
 
Clinical measurements: A subset of this group, consisting of 25 healthy individuals 
(age range: 18-52 years) who volunteered to be screened for a pharmacogenetic 
study, were tested for the ancillary hypothesis of CYP3A5 genotype association with 
blood pressure and creatinine clearance. Subjects were brought to the UNC General 
Clinical Research Center (GCRC), where they were examined and donated blood 
and urine samples. GCRC nurses who were blind to subject genotypes and medical 
histories performed and recorded all clinical measurements. Creatinine clearance 
was calculated by the Cockcroft-Gault equation (132). 
 
Genomic DNA collection and isolation: Subjects were instructed to swish 
vigorously with 10 mL Scope® mouthwash for 1 minute and expel the rinse into 50-
mL conical vials. Samples were placed at room temperature for a maximum of 48 
hours until further processing. DNA was extracted from rinse samples with the use of 
either a QIAamp DNA Blood Mini Kit (Qiagen, Inc.; Valencia, CA) or a Puregene 
DNA Isolation Kit for mouthwash samples (Gentra Systems) according to the 
manufacturer’s instructions. Total DNA concentrations were determined by 
spectrophotometry at 260 nm. 
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CYP3A5 genotype determinations: The CYP3A5*3 variant was identified by 
polymerase chain reaction (PCR). The forward primer for this reaction was 5'-
CCTGCCTTCAATTTTTCACTG-3', which anneals at position 22719 (Genbank no. 
AC005020); the reverse primer was 5'-GCAATGTAGGAAGGAGGGCT-3', which 
anneals at position 24161 (Genbank no. AC005020). PCR was performed as follows: 
50 ng DNA was initially denatured at 92°C for 5 minutes followed by 35 cycles of 
denaturation at 92°C for 30 seconds, annealing at 61°C for 30 seconds, and 
synthesis at 72°C for 2 minutes. The final elongation was carried out for 5 minutes at 
72°C. The unincorporated nucleotides and primers were removed as described 
above. Sequencing was carried out on an ABI Prism 3700 Automated Sequencer. 
The nested primers used to sequence were 5'-TAATATTCTTTTTGATAATG-3' (f) 
and 5'-CATTCTTTCACTAGCACTGTTC-3' (r). Sequences were assembled using 
the Polyphred program (University of Washington, Seattle), which automatically 
detects the presence of heterozygous SNP substitutions by fluorescence-based 
sequencing of PCR products. 
 
Statistical analyses: Microsomal CYP3A5 content and MDZ 1’-hydroxylation were 
compared between genotypes with the Wilcoxon signed-rank test for non-parametric 
distributions. Differences between human subject genotype groups were assessed 
by ANOVA and Fisher’s exact test for continuous and categorical variables, 
respectively. 
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RESULTS 
CYP3A5 genotype predicts renal CYP3A activity: The average CYP3A5 content 
(1.98 pmol/mg; n=5) of microsomes from *1/*3 kidneys exceeded the average of 
those from *3/*3 kidneys (n=16; p=0.0001), which was at or below the limit of 
quantitation (Figure I-IA). None of the kidneys were *1/*1. CYP3A4 was not detected 
with a CYP3A4-specific antibody in any of the microsomal preparations. Mean 
microsomal CYP3A activity, reflected by MDZ 1’-hydroxylation, was 18-fold higher in 
*1/*3 kidney microsomes (8.04 pmol/min/mg) than in those from *3/*3 kidneys (0.43 
pmol/min/mg; p=0.0137; Figure I-IB). The *1/*3 outlier indicated by arrows in Figure I 
also bore a *7 allele and was probably a compound heterozygote. Removal of this 
outlier slightly lowered p values.  
 
CYP3A5 genotype predicts blood pressure: The CYP3A5 A6986 (*1 allele) 
frequency among the 89 African-Americans was 0.7. Among the 25-subject subset 
(TABLE II-A), CYP3A5 genotype associated with seated systolic BP (SBP), mean 
arterial pressure (MAP), the product of SBP and heart rate (SBP*HR, an indicator of 
left-ventricular oxygen consumption), and Cockcroft-Gault creatinine clearance 
(CrCl). The *1/*1 group averaged the highest value for each measure. Average *1/*1 
SBP exceeded that of the *3/*3 group by 19.3 mm Hg (Figure I-II) and a gene-dose 
effect was apparent. CYP3A5 genotype associated significantly with combined BP 
strata (p=0.0048; TABLE II-A) from the Sixth Report of the Joint National Committee 
on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-
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VI; N=Optimal or Normal [SBP <130 and DBP <85]; H=High-Normal or higher [SBP 
≥130 or DBP ≥85]) (133).  
Sex-specific analysis detected CYP3A5 genotype associations with SBP, 
MAP, and estimated CrCl among females (TABLE II-A); similar trends were noted 
among the smaller sample of males, but these did not reach statistical significance. 
In multiple regression analyses, sex and genotype accounted for 70% of the 
variability in SBP. When compared to non-*1/*1 females, *1/*1 males showed more 
than a 20-fold increased risk of high-normal or higher BP (p=0.0002).  
Subject age, averaging roughly 25 years, did not vary between genotype 
groups. Age and body mass index (BMI) effects upon BP were non-significant. 
Genotype association with BMI, diastolic blood pressure (DBP), pulse pressure (PP), 
and HR did not reach statistical significance.  
 
DISCUSSION 
The CYP3A5*1 allele associates with CYP3A5 expression in the human kidney- a 
finding which was previously reported for liver and intestine. However, in the liver 
and intestine, there is also substantial CYP3A4 expression (25, 26). As a result, 
hepatic and intestinal aggregate CYP3A activities associate only weakly with the 
CYP3A5*1 allele. In contrast, CYP3A4 was not detected in renal microsomes, and 
mean CYP3A activity differed markedly between CYP3A5 genotype groups. 
The preliminary finding of CYP3A5 genotype association with resting BP 
among healthy adults may be consistent with a role for CYP3A enzymes in BP 
control. Young adults with supernormal BP have an increased long-term risk of 
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death due to cardiovascular and coronary heart disease (134); the identification of 
common genetic polymorphisms relevant to BP control is thus an important line of 
investigation. If shown true, this conjecture might portend a role for inhibition of 
CYP3A5 activity or expression in the treatment of some forms of hypertension. 
The CYP3A5 A6986 allele frequency among this cohort of African-Americans 
agrees roughly with a previous report (47). This frequency exceeds those among all 
other ethnic populations studied to date (25, 47). Inter-ethnic differences in the 
prevalence of sodium-sensitivity (124) parallel those of hypertension (123), with 
African-Americans having the highest global prevalence of each. A possible link 
between CYP3A5 activity and the high prevalence of sodium-sensitive hypertension 
among African Americans may merit further study. 
48 
0
1
2
3
4
5
6
CY
P3
A
5 
c
o
n
te
n
t (p
m
o
l/m
g)
0
2
4
6
8
10
12
14
16
18
1'
-
hy
dr
o
x
yl
a
tio
n
 
fo
rm
at
io
n
 
(pm
o
l/m
in
/m
g)
 
 
FIGURE II-1. CYP3A activity and CYP3A5 content in *1/*3 and *3/*3 renal 
microsomes from 21 organ donors. 
A: CYP3A5 content differs between *1/*3 and *3/*3 renal microsomes (p=0.0001). B: 
MDZ 1’-hydroxylation differs between *1/*3 and *3/*3 renal microsomes (p=0.0137). 
Analysis of DNA from the *1/*3 outlier, indicated by arrows, revealed the inactivating 
*7 variant. Bars show average values. 
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FIGURE II-2. Seated systolic blood pressure among 25 healthy African 
American adults by CYP3A5 genotype. 
SBP varies among genotypic groups (p=0.0007). Nurses blinded to subject 
genotypes performed all measurements. Bars show average values. 
 
 
 
 
 
 
 
*1/*1                    *1/*3                      *3/*3             
 n=9                      n=9                       n=7                   
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All Subjects   n=9   n=9   n=7  
Females   n=4   n=6   n=5  
Values are shown as mean (SD). BMI, body mass index; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; mean arterial pressure (MAP); PP, pulse 
pressure; HR, heart rate; CrCl, creatinine clearance; JNC-VI, combined BP stratum 
from the Sixth Report of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure; N, Optimal or Normal (SBP <130 
and DBP <85); H, High-Normal or higher (SBP ≥130 or DBP ≥85). 
 
 
 
 
 
TABLE II-A. Blood pressure and creatinine clearance by CYP3A5 genotype 
 *1/*1 *1/*3 *3/*3 p 
Age (years) 24.5 (10.7) 25.0 (8.0) 25.0 (8.5) 0.9933 
BMI (kg/m2) 30.3 (8.1) 23.9 (4.6) 26.2 (2.8) 0.0851 
SBP (mm Hg) 136.0 (7.9) 121.6 (8.4) 116.7 (11.0) 0.0007 
DBP (mm Hg) 71.4 (5.1) 68.1 (10.1) 63.3 (6.5) 0.1283 
MAP (mm Hg) 92.9 (3.8) 85.9 (9.0) 81.1 (6.5) 0.0075 
PP (mm Hg) 64.6 (10.3) 53.4 (7.0) 53.4 (10.6) 0.0309 
HR (min-1) 78.9 (15.3) 73.9 (9.0) 70.6 (8.3) 0.3633 
SBP*HR (mm Hg*min-1) 10743.1 (2253.3) 8948.6 (1006.2) 8189.6 (810.8) 0.0088 
JNC-VI stratum (N/H) 2/7 8/1 6/1 0.0048 
CrCl (ml/min) 147.2 (30.9) 106.9 (23.7) 110.4 (10.5) 0.0035 
Age (years) 20.8 (2.8) 20.8 (2.6) 25.8 (9.6) 0.3426 
SBP (mm Hg) 130.8 (6.2) 117.5 (3.9) 112.2 (9.1) 0.0039 
MAP (mm Hg) 91.9 (3.8) 82.5 (2.9) 80.2 (7.6) 0.0127 
CrCl (ml/min) 156.9 (16.6) 114.7 (24.3) 111.0 (10.4) 0.0059 
Males   n=5   n=3   n=2  
Age (years) 27.6 (14.0) 33.3 (9.1) 23.0 (7.1) 0.6439 
SBP (mm Hg) 140.2 (6.8) 129.7 (9.8) 128.0 (5.7) 0.1355 
CrCl (ml/min) 139.5 (39.2) 91.4 (15.4) 109.0 (14.9) 0.1661 
  
 
 
 
 
CHAPTER III: CYP3A5 HAPLOTYPE RECONSTRUCTION 
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SUMMARY 
Cytochrome P450 3A5 (CYP3A5) is a member of the CYP3A enzyme subfamily, 
which catalyzes the metabolism of the majority of marketed drugs. CYP3A5 is 
expressed polymorphically between individuals, and the frequency of expression 
varies between ethnic groups. An individual’s ability to express CYP3A5 is defined 
by known single nucleotide polymorphisms (SNPs) in the CYP3A5 gene. The 
A6986G SNP distinguishes the CYP3A5*1 (or “full-expresser”) allele from the 
dysfunctional variant *3 allele, the major expression-determining allele common to all 
populations. Considerable interest has arisen in the potential of CYP3A5 genotype 
as a predictor of drug metabolism and as a disease risk factor. Among blacks, the 
predictive power of the *3 allele for CYP3A5 expression may lowered by the 
presence in this group of two additional alleles, called *6 and *7. In this chapter, an 
expectation-maximization (EM) algorithm is used to reconstruct CYP3A5 haplotypes 
among a sample of African-Americans who were genotyped for the three 
dysfunctional alleles. This method deduced the presence of four CYP3A5 
haplotypes: the full-expresser haplotype and three single-variant haplotypes. This 
finding may obviate the need for future molecular CYP3A5 haplotyping assays. 
Statistical haplotype reconstruction may restore the predictiveness of CYP3A5 SNPs 
and lower genotyping costs.  
INTRODUCTION 
The CYP3A subfamily consists of CYP3A4 and CYP3A5 in adults. While CYP3A4 
expression is universal, CYP3A5 is expressed by a minority of individuals in most 
populations but by a majority of blacks of African descent (25, 53, 55). Interpersonal 
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variance in CYP3A5 activity may be clinically important. There is a potential for 
CYP3A5 activity to predict an individual’s ability to metabolize drugs. For instance, a 
number of studies have demonstrated a higher dose requirements for the 
immunosuppressant CYP3A substrate tacrolimus among CYP3A5-expressing organ 
recipients, compared to non-expressers (36, 38, 135-137). CYP3A5 and CYP3A 
activity may additionally have roles in the modification of disease risk, as suggested 
by CYP3A metabolism of estrogens (138-144), androgens (145-148), and 
corticosteroids (86, 149-152). There have been intriguing but inconstant associations 
of CYP3A5 genotype with cancers of the prostate, lung, and breast (153-158); 
hematological malignancies (159, 160); early puberty (161); and blood pressure (30, 
54, 162-173). 
The genetic basis for the bulk of CYP3A5 polymorphism was first described 
by Kuehl, et al. (25), who discovered an A-to-G transition (A6986G) that activates an 
alternative splice-acceptor site in the third intron of the CYP3A5 gene. The presence 
of guanine at this position defines the *3 allele, a dysfunctional variant that produces 
negligible amounts of functional enzyme, as compared to the functional *1 allele. 
Inter-group differences in the prevalence of CYP3A5 expression mainly reflect 
variation in the frequency of *3, which is 0.85-0.95 among whites (25, 55), 0.76-0.78 
among Chinese (48, 56) and 0.2-0.3 among blacks (25, 30, 55). The *3 allele 
predicts whether CYP3A5 is expressed in the liver (25), intestine (26), and kidney 
(30). But CYP3A5 genotype at the 6986 site may have lower predictive power for 
blacks than for other groups. 
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 Kuehl, et al. and Hustert, et al. identified two other low-expressor alleles, *6 
and *7, that respectively reflect G14690A and 27131-32insT SNPs. These are 
specific to blacks at frequencies of roughly 0.15 for *6 and 0.10 for *7 (25, 47). The 
G14690A SNP causes aberrant splicing, while 27131-32insT causes a frame shift 
resulting in premature termination of transcription. Each of the resulting alleles has 
been shown to decrease CYP3A5 protein expression (25, 30, 45, 47).  
     The presence of multiple dysfunctional SNPs in a particular gene can lower the 
power of the genotype at any individual locus in the gene to predict phenotype. In 
such situations, it may be important to determine haplotype. Experimental methods 
for directly determining haplotypes, such as the creation of yeast artificial 
chromosomes (174) or the creation of mouse-human hybrid cell lines (175), can be 
too technically difficult, laborious, or expensive for large-scale studies. While a 
subject’s haplotype may also be deduced from genotypes of the subject’s family 
members (176), collection of these additional samples may be impractical at least. It 
may also be possible to reconstruct haplotypes by using statistical methods to infer 
phase from genotypes at linked loci. One of the most popular approaches for this is 
based upon maximum likelihood and uses the expectation-maximization (EM) 
algorithm (177-179), which can produce accurate estimates of haplotype frequencies 
for a wide range of settings (180).  
The EM algorithm was used to resolve CYP3A5 genotypes at the 6986, 
14690, and 27131 positions among a group of African-Americans into four 
haplotypes. The implications of CYP3A5 haplotyping for CYP3A phenotype 
prediction will be discussed. 
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METHODS 
Human subjects: 117 unrelated self-identified African-American adults were 
genotyped for the CYP3A5 *3, *6, and *7 SNPs. In=person informed consent was 
obtained for all subjects. The study was approved by the Institutional Review Board 
of the University of North Carolina School of Medicine. Genotypes were obtained by 
genomic DNA sequencing, as described (25). 
 
CYP3A5 genotype determinations: CYP3A5 exon 3B was amplified for 
identification of the CYP3A5*3 variant by polymerase chain reaction (PCR). The 
forward primer for this reaction was 5'-CCTGCCTTCAATTTTTCACTG-3', which 
anneals at position 22719 (Genbank no. AC005020); the reverse primer was 5'-
GCAATGTAGGAAGGAGGGCT-3', which anneals at position 24161 (Genbank no. 
AC005020). PCR was performed as follows: 50 ng DNA was initially denatured at 
92°C for 5 minutes followed by 35 cycles of denaturation at 92°C for 30 seconds, 
annealing at 61°C for 30 seconds, and synthesis at 72°C for 2 minutes. The final 
elongation was carried out for 5 minutes at 72°C. The unincorporated nucleotides 
and primers were removed as described above. Sequencing was carried out on an 
ABI Prism 3700 Automated Sequencer. The nested primers used for sequencing 
were 5'-TAATATTCTTTTTGATAATG-3' (f) and 5'-CATTCTTTCACTAGCACTGTTC-
3' (r). The primers used to amplify the exon 7 deletion in CYP3A5*6 were 5'-
GGTCATTGCTGTCTCCAACC-3' (f) and 5'-TCAAAAACTGGGGTAAGGAATGT-3' 
(r). The PCR was performed as above with an annealing temperature of 59°C. 
Sequencing was carried out using nested primers 5'-TATGACTGGGCTCCTTGACC-
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3' (f) and 5'-TGGAATTGTACCTTTTAAGTGGA-3' (r). PCR for the *7 insertion was 
performed with the following primers: 5'-AAATACTTCACGAATACTATGATCA-3' (f) 
and 5'-CAGGGACATAATTGATTATCTTTG-3' (r). Sequences were assembled using 
the Polyphred program (University of Washington, Seattle), which automatically 
detects the presence of heterozygous SNP substitutions by fluorescence-based 
sequencing of PCR products. 
     
Haplotype reconstruction: CYP3A5 genotypes at each locus were assessed for 
Hardy-Weinberg equilibrium and were subjected to the EM algorithm with Arlequin 
2.0 software (181). The software was programmed to allow 300 initial conditions for 
haplotype frequency estimation, 200 initial conditions for the linkage disequilibrium 
test with 20,000 permutations, and 200 initial conditions for the bootstrap procedure 
with 100,000 replicates. 
 
RESULTS 
The observed CYP3A5*3, *6, and *7 allele frequencies among 117 African-
Americans were 0.329, 0.150, and 0.103, respectively; these are consistent with 
previous studies (25, 47). Complete linkage disequilibrium (D’ =1.0) was observed 
between each pair of loci. The frequencies and estimated standard deviations of 
haplotypes deduced by EM are shown in Figure III-I. Of the 8 possible haplotypes 
that might be constructed from the 3 biallelic CYP3A5 loci (23 = 8), only the full-
expresser (*1-*1-*1) and the three singly-variant haplotypes are detected. The 
deduced frequency of the full-expresser haplotype (*1-*1-*1) is 0.426 (0.035). The 
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distributions of diplotypes (haplotype combinations) among CYP3A5 expression 
phenotypes are shown in FIGURE III-1. 
  
TABLE III-A. CYP3A5 allele frequencies among 117 African-Americans 
Genotype (N) Allele Frequency Std. Error *1/*1 *1/*X *X/*X HWE χ
2
 P 
*3 (6986G) 0.329 0.043 54 49 14 0.311 0.675 
*6 (14690A) 0.150 0.033 83 33 1 1.382 0.240 
*7 (27131insT) 0.103 0.028 94 22 1 0.054 0.817 
 
 
TABLE III-B. CYP3A5 haplotype frequencies among African-Americans 
Haplotype Constituent Alleles Frequency Std. Dev. 
*1-*1-*1 6986A-14690G-27131wt  0.426 0.035 
*3-*1-*1 6986G-14690G-27131wt  0.327 0.033 
*1-*6-*1 6986A-14690A-27131wt  0.158 0.026 
*1-*1-*7 6986A-14690G-27131insT 0.089 0.020 
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FIGURE III-1. Reconstructed CYP3A5 diplotype and phenotype frequencies.  
The frequency of each diplotype deduced by EM is indicated; the proportion of each 
diplotype among its respective functional category is shown in parentheses. H: high 
CYP3A5 activity; I: intermediate activity; L: low activity 
 
 The presence of multiple unphased causative SNPs threatens to complicate 
attempts to associate gene function with phenotype. It is hoped that haplotyping can 
improve the power to detect gene-phenotype associations. Using the data presented 
in Chapter II, comparison of power versus sample size for homozygous expresser 
and nonexpresser groups based upon genotype at 6986 or haplotype shows mixed 
results (FIGURE III-2). Use of CYP3A5 haplotype is predicted to slightly reduce 
power at a given sample size for systolic blood pressure, but it is predicted to greatly 
increase power to detect differences in body mass index or creatinine clearance. 
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FIGURE III-2. Power versus sample size for CYP3A5 genotype and haplotype. 
Curves compare power as a function of sample size between genotype at CYP3A5 
A6986 (bold line) and CYP3A5 haplotype (light line). A. systolic blood pressure. B. 
body mass index. C. creatinine clearance. 
 
DISCUSSION 
If taken to be representative of African-Americans broadly, these data would imply 
that CYP3A5 expressers are roughly 67% of this group, by the Hardy-Weinberg 
equilibrium equation. This figure exceeds estimated proportions of expressers 
among other groups- 30-40% among Asian groups, 10-20% among whites- but is 
much lower than estimates of roughly 90% based upon the *3 allele in this and other 
studies. Among 6986 *1/*1 homozygotes, less than 25% would have two truly 
A B 
C 
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functional CYP3A5 genes, nearly 75% would have only one, and 3% would be non-
expressers. Of those deemed to be expressers based upon 6986 genotype (*1/*1 or 
*1/*3) nearly 25% would be true non-expressers. Less than 40% of true non-
expressers would be identified on the basis of a *3/*3 genotype. In a hypothetical 
scenario of CYP3A5 expression perfectly predicting a phenotype, the presence of 
true non-expressers in these proportions among presumed expressers would lower 
predictiveness by 25%. In addition to position 6986, the determination of genotypes 
14690 and 27131 and the haplotype combinations among these sites is likely to be 
important in evaluating associations between CYP3A5 expression and various 
phenotypes among black subjects.  
African-American CYP3A5 haplotypes among these sites can be inferred 
from population data with the E-M algorithm. This computational approach may 
improve the predictive power of CYP3A5 genotype and likely renders molecular 
haplotyping methods unnecessary. The apparent lack of recombination between 
these positions is perhaps not surprising given the relatively short distances between 
them (<21 kb). Confirmation of non-recombination among these sites may also be 
used to lower the costs of CYP3A5 genotyping by allowing analysis of one locus at a 
time and stopping once two variant alleles have been identified for a particular 
subject, thus reducing the number of reactions that must be performed to accurately 
predict an individual’s phenotype. 
  
 
 
 
 
CHAPTER IV: IN VITRO STUDIES OF 6β-HYDROXYCORTICOSTERONE 
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SUMMARY 
Excessive sodium reabsorption by the kidney may cause increased plasma volume 
and a resultant hypertension. Sodium sensitivity, independently and as a cause of 
hypertension, is associated with an increased risk of premature death. Cytochrome 
P450 3A (CYP3A) enzymes have been proposed to alter renal sodium reabsorption 
by catalyzing the conversion of glucocorticoids such as cortisol or corticosterone to 
6β-hydroxylated metabolites with altered activity. The mechanisms by which these 
metabolites act in the kidney have not previously been identified.
 
This chapter details an exploration of the effects of corticosterone and 6β-
hydroxycorticosterone on gene expression in cultured renal collecting duct cells and 
an evaluation of the hypothesis that 6β-hydroxycorticosterone exhibits 
physiologically relevant inhibition of 11β-hydroxysteroid dehydrogenase type 2 (11β-
HSD2), which prevents inappropriate activation of the mineralocorticoid receptor 
(MR) by glucocorticoids. The results show that, on its own, 6β-hydroxycorticosterone 
does not markedly influence epithelial sodium channel α-subunit (ENaC-α) gene 
expression but increases ENaC-α mRNA levels when it is applied in addition to B, its 
parent compound. It is suggested that this activity reflects the ability of 6β-
hydroxycorticosterone to inhibit inactivation of corticosterone by the 11β-HSD2 
enzyme- a contention which is supported by enzyme kinetic data that show that 6β-
hydroxycorticosterone limits corticosterone conversion in a manner consistent with 
reversible, competitive inhibition. 
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Exploration of this phenomenon may provide insights into the renal control of 
electrolyte balance and blood pressure and may suggest new pharmacologic targets 
for antihypertensive therapy and the control of sodium sensitivity. 
 
INTRODUCTION 
CYP3A enzymes catalyze the oxidative metabolism of a wide variety of lipophilic 
molecules, including steroids. The results of animal and in vitro studies indicate that 
CYP3A-catalyzed 6β-hydroxylation of corticosterone in the kidney can alter renal 
sodium transport. 6β-hydroxycorticosterone increases sodium transport across 
cultured A6 Xenopus laevis toad kidney cells and induces sodium retention in 
spontaneously hypertensive rats (SHR). Some effects of 6β-hydroxycorticosterone 
may mimic classic mineralocorticoid activity, but 6β-hydroxycorticosterone appears 
to act through a binding site for corticosterone that is distinct from MR or the 
glucocorticoid receptor (GR) (81). The identity of this binding site remains unknown. 
Subsequent studies demonstrate that some high-affinity binding sites for 
corticosterone in mammalian renal collecting duct consist of 11β-hydroxysteroid 
dehydrogenase type 2 (11β-HSD2) (126, 127). 11β-HSD2 is an NAD+-dependent 
enzyme that limits glucocorticoid activation of MR in aldosterone-sensitive epithelia 
by catalyzing the conversion of cortisol and corticosterone to their respective 11-
oxidized metabolites (cortisone and 11-dehydrocorticosterone), which are weaker 
MR agonists.  
Human genetic absence of 11β-HSD2, encoded by the HSD11B2 gene, 
causes the syndrome of apparent mineralocorticoid excess (AME), so named 
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because its classic features of hypertension and hypokalemia are suggestive of high 
aldosterone levels. But aldosterone and renin levels in AME are low, reflecting a 
sodium-replete state caused by cortisol-mediated MR activation (182, 183). 
The genomic actions of MR action can be divided into early and late phases. 
Agonist-bound MR acutely (as early as 30 minutes) increases transcription of genes 
such as the serum-and-glucocorticoid regulated kinase-1 (SGK1) that regulate the 
activities of the Na+/K+-ATPase and the amiloride-sensitive epithelial sodium channel 
(ENaC), which participate in distal tubular sodium reabsorption and exert final 
regulatory control over sodium homeostasis. MR agonism subsequently leads to 
induction of mRNAs for Na+/K+-ATPase and ENaC subunits (184, 185).  
Mice in which the HSD11B2 gene has been inactivated are hypertensive and 
hypokalemic- a finding that reinforces the enzyme’s physiologic importance (186, 
187). Milder genetic or acquired deficiencies in 11β-HSD2 activity can also cause 
clinical phenotypes. Ingestion of licorice and glycyrrhetinic acid derivatives such as 
carbenoxolone can cause an AME-like pseudohyperaldosteronism among 
susceptible individuals by inhibiting 11β-HSD2 (188). 
11β-HSD2 is co-expressed with CYP3A isoforms in MR-expressing segments 
of mammalian renal distal tubules and collecting ducts (80, 84, 126, 189). In addition 
to glucocorticoids, the two enzymes share some affinity for structurally-related 
molecules. For instance, bile acid CYP3A substrates and products can competitively 
inhibit 11β-HSD2 activity (190, 191). In this chapter, I test the hypothesis that 6β-
hydroxycorticosterone competitively inhibits 11β-HSD2 and that its effects on sodium 
transport partly reflect this inhibition. 
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METHODS 
Cell Culture: mIMCD-K2 cells, derived from inner medullary collecting ducts of 
SV40-transgenic male mice (192), were kindly provided by the laboratory of Dr. 
Bruce Stanton (Dartmouth University) at passage 14. Cells were seeded at a density 
of 4000 cells/cm2 and grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), penicillin (100,000 U/liter), and 
streptomycin (100,000 µg/liter); all were purchased from Gibco/Invitrogen. Cells were 
maintained in 24- or 48-well plates (Costar) in incubators maintained at 37°C and 
5% CO2 until they reached at least 90% confluence.  
For gene expression studies and enzyme assays, cells between passages 19 
and 22 were grown to 90% confluence maintained in 24- or 48-well tissue culture 
plates (Costar). The FBS used in these studies was charcoal-dextran-stripped to 
remove serum steroids, in accordance with published methods (193), by incubating 
at 45°C for 30 min with an equal volume of 0.25% activated charcoal/0.025% 
dextran in 0.01 M Tris/HCl (pH 8.0 at 4°C); charcoal was removed by centrifugation.  
All steroids and chemicals used for gene expression and enzyme assays 
were purchased from Sigma-Aldrich, except for 6β-hydroxycorticosterone 
(Steraloids, Inc.; Newport, RI). Aldosterone, corticosterone, 6β-
hydroxycorticosterone, spironolactone, and mifepristone (RU486) were stored as 
stock solutions (10 mM in 100% ethanol) at -20°C until use. Carbenoxolone was 
stored in water (10 mM) at 4°C. 
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Gene Expression Studies: Steroids and other chemicals were diluted to the 
indicated concentrations in DMEM with 10% fetal bovine serum that was treated with 
charcoal-dextran to remove steroids. Final ethanol concentrations were 0.1% in all 
preparations. Suspensions were added to cells for the indicated times, after which 
RNA was extracted.  
 
TaqMan RT-PCR: Cells in each well were lysed with 200 µL of Nucleic Acid 
Purification Lysis Solution (Applied Biosystems, Foster City, CA) diluted by half with 
phosphate-buffered saline (Gibco). RNA was isolated in an RNA purification tray 
with the ABI Prism 6700 automated nucleic acid workstation (PE Biosystems). RT-
PCR was performed in the ABI Prism 7700 sequence detector (PE Biosystems); 
cDNA was synthesized by reverse transcription prior to PCR in the 7700 system. 
During amplification, fluorescences of FAM, TAMRA, and ROX (passive reference 
dyes) were measured by the 7700 sequence detector. For mRNA expression, each 
sample’s β-actin Ct was used as the standard. Relative mRNA levels were 
calculated with the ddCt method: relative expression = 2-(Ct gene of interest – Ct β-actin). 
TaqMan primer and probe sequences are shown in TABLE IV-A. 
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TABLE IV-A. List of TaqMan primers and probes 
Gene Type Sequence (5’-3’) 
HSD11B1 Forward AGACACAGAAACAGCTATGAAG 
 Reverse TGATGATCTCCAGGGCGCA 
 Probe f-TGACGCCCTAGCTTCTCCCAAGGAG-q 
HSD11B2 Forward GACATCAGCCGTGTTCTGGA 
 Reverse GGCCAGCGTTGTTAACCAGA 
 Probe f-ATCACCAAGGCCCACACGGCC-q 
MR Forward GTGTCAAGCTCTACTTTACGA 
 Reverse ACACCCAGAAGCCTCATCT 
 Probe f-CTGGATCCTCAAGACCTTCCAAGATC-q 
GR  Forward ACATGTTAGGTGGGCGCCA 
 Reverse GTGTAAGTTTCTGAATCCTGGTA 
 Probe f-CCTTGCCCATTTCACTGCGGCAATC-q 
ENaCα Forward AGCGCGTCTTCCAGTGTAC 
 Reverse GATTTGTTCTGGTTGCACAGT 
 Probe f-CAACAATCCCCAAGTGGACAGGAAGG-q 
ENaCγ Forward CACTGGTCGGAAGCGGAAA 
 Reverse GCACAGTCAGAGGTGTCATT 
 Probe f-ACAAGGCTTCTAATGTCATGCACGTTC-q 
PGK-CYP3A5 Forward CTTCAGCTGATGATTGACTCC 
 Reverse TATTGACTGGGCTGCGAGCT 
 Probe f-TCGAAAGAAACTGAGTCCCACAAAGCTCTGT-q 
CYP3A11 Forward AGAACTTCTCCTTCCAGCCTTGTA 
 Reverse GAGGGAGACTCATGCTCCAGTTA 
 Probe f-CTAAAGGTTGTGCCACGGGATGCAGT-q 
PPARγ Forward AGACATGAGCCTTCACCCC 
 Reverse AGAAGGAACACGTTGTCAGC 
 Probe f-CAAGTCCTTGTAGATCTCCTGGAGC-q 
Endothelin-1 Forward TGCCACCTGGACATCATCTG 
 Reverse ACGCTTGGACCTGGAAGAAC 
 Probe f-TCCCGAGCGCGTCGTACCGTATG-q 
β-Actin Forward CTGCCTGACGGCCAGGTC 
 Reverse CAAGAAGGAAGGCTGGAAAAGA 
 Probe f-CACTATTGGCAACGAGCGGTTCCG-q 
f, Reporter dye (FAM:6-carboxyfluorescein); 
q, Quencher dye (TAMRA: 6-carboxytetramethyl1-rhodamine) 
 
 
 
Cell Homogenate Enzyme Assays: Cells were scraped into a homogenization 
buffer containing 250 mM sucrose and 10 mM Tris-HCl (pH 7.5) with Protease 
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Inhibitor Cocktail (Sigma). Cells were disrupted by sonication. Homogenates were 
incubated for 3 h at 37°C with 10 nM corticosterone and 2nM [1,2,6,7-3H]-B (Sigma; 
70-100 Ci per mmol) in homogenization buffer with and without 1 mM NAD. Samples 
were incubated for 3 h at 37°C and the reaction was stopped on ice. Steroids were 
extracted by adding two volumes of ethyl acetate. Samples were vortexed vigorously 
for 1 min and then centrifuged at 10,000 xg for 5 min. The upper ethyl acetate layer 
was removed, extraction was repeated, and the extracts were pooled. Ethyl acetate 
was evaporated from pooled extracts by centrifuging under vacuum pressure. The 
residue was dissolved in a small amount of ethanol that contained 10 nmol each of 
unlabeled corticosterone and 11-dehydrocorticosterone. 11β-HSD2 activity was 
assessed by thin-layer chromatography (TLC) (194). Samples were dotted onto 
silica gel TLC plates with a 254-nm fluorescent indicator (Whatman). Unlabeled 
steroid standards were added in separate lanes. Plates were developed in glass 
beakers containing a mobile phase of 92% chloroform/8% ethanol and dried at room 
temperature. Plates were visualized under short-wave ultraviolet light; fluorescence-
quenched spots aligning with corticosterone and 11-dehydrocorticosterone 
standards were marked, cut from the plates, and placed separately into vials 
containing Scintiverse BD Cocktail (Fisher Scientific). After a brief shaking, vials 
were placed in a LKB RackBeta scintillation counter and counts per minute (CPM) 
were recorded. The percent conversion for each sample was calculated by dividing 
the 11-dehydrocorticosterone CPM value by the sum of the corticosterone and 11-
dehydrocorticosterone CPM values. 
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Whole-Cell Enzyme Assays: DMEM/10% charcoal-stripped FBS, containing 2nM 
[1,2,6,7-3H]-B and indicated concentrations of unlabeled corticosterone, was applied 
to cells. At the end of incubation, medium from each well was removed for steroid 
extraction. Sample processing and data collection procedures were conducted as for 
whole-cell assays. The amount of 11-dehydrocorticosterone produced by each 
incubation was calculated by multiplying the corresponding percent conversion by 
the total amount of corticosterone (tritiated and unlabeled) added to the incubation. 
 
Analysis: Substrate-velocity curves were fitted by nonlinear regression with 
GraphPad Prism (GraphPad Software, Inc.; San Diego, CA). Modeling assumed that 
conversion of B obeys Michaelis-Menten kinetics and that its inhibition by 6β-OHB 
was competitive and reversible. 
Variation among the means of multiple groups was evaluated with analysis of 
variance (ANOVA). Pairwise differences were analyzed with the Student’s t-test. 
Dose- and time-dependent effects were explored by linear regression where noted. 
Analytical and graphing software included Prism, JMP (SAS Institute, Inc.; Cary, 
NC), and Microsoft Excel. Unless indicated, all experiments were conducted in 
triplicate and means and standard deviations are reported. 
 
RESULTS 
Gene expression: TaqMan analysis indicated baseline signals corresponding to the 
mRNAs for MR, GR, HSD11B2, ENaCα, ENaCγ, PPARγ, and endothelin-1 (data not 
shown). Therefore, it was deemed that mIMCD-K2 cells have an mRNA expression 
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pattern retain reminiscent of collecting duct cells in vivo. CYP3A11 mRNA was not 
reliably detected in mIMCD-K2 cells at baseline. HSD11B1 mRNA was also detected 
and its ddCt value was roughly 7 times that of HSD11B2. The relative signal for GR 
exceeded that of MR by more than 70-fold. 
 
Gene expression responses to steroid treatment: Cells were treated with 10-6 M 
corticosterone for up to 8 hours and with varying doses of aldosterone and 
corticosterone for 24 hours. As shown in FIGURE IV-1, SGK1 mRNA levels respond 
to corticosterone treatment by 2 hours. ENaCα mRNA was dose-dependently 
induced by both steroids at 24 hours, although the maximum effect of aldosterone 
was nearly three times that of corticosterone. The IC50, the dose at which 50% of the 
maximum effect is produced, was roughly 5x10-7 M for each. 
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FIGURE IV-1. mIMCD-K2 cells respond to corticosterone treatment.  
A: Treatment with 10-6 M B from 0 to 8 h produces a short-term increase in SGK1 
mRNA response. B: ENaCα mRNA levels are increased aldosterone and 
corticosterone at 24 h. 
 
Comparison of 6β-hydroxycorticosterone to carbenoxolone: Cells were 
incubated with varying concentrations of 6β-hydroxycorticosterone and 
carbenoxolone, the known 11β-HSD2 inhibitor, in the absence of corticosterone for 
24 h (FIGURE IV-2A). While some dose effects may be apparent, they were 
relatively minor. FIGURE IV-2B shows the ability of 6β-hydroxycorticosterone and 
carbenoxolone to alter the responsiveness of ENaCα mRNA levels to corticosterone. 
These data demonstrate that 6β-hydroxycorticosterone behaves like carbenoxolone 
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in an important manner: its major effects on ENaCα mRNA levels are exhibited only 
in the presence of corticosterone. 6β-hydroxycorticosterone was generally more 
effective than carbenoxolone at the same concentrations under most conditions. 
Most but not all assays indicated a left-shift in the efficacy of corticosterone when 
6β-hydroxycorticosterone was added.  
 
 
 
 
 
 
 
 
 
FIGURE IV-2. 6β-hydroxycorticosterone and carbenoxolone effects on ENaCα 
mRNA levels.  
A: Cells were treated for 24 h with varying concentrations of CBX or 6β-OHB alone. 
B: Cells were treated for 24 h with 10-6 or 10-5 M of either CBX or 6β-OHB in the 
presence of B (10-8 or 10-7 M). 
 
6β-hydroxycorticosterone alters ENaCα response to corticosterone: Data from 
24-h incubations of mIMCD-K2 cells with varying concentrations of corticosterone 
with or without 6β-hydroxycorticosterone, RU486, and/or spironolactone (all at 10-5 
M) may suggest that 6β-hydroxycorticosterone protects the activity of corticosterone. 
6β-hydroxycorticosterone may have had some minor effects in this assay on the 
shape of the dose-effect curve for corticosterone but its major effects occurred when 
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either MR or GR were blocked. As shown in FIGURE IV-3A, the GR antagonist 
RU486 (R) produced a two-order left-shift in dose-effect, likely by blocking the low-
efficacy GR and thus freeing corticosterone to bind to the high-efficacy MR. But the 
addition of 6β-hydroxycorticosterone in this setting nearly completely flattens this 
response, which may reflect 6β-hydroxycorticosterone antagonism of MR, as 
previously reported (81) and as suggested by FIGURE IV-4. The addition of the MR 
antagonist spironolactone (S) to corticosterone (FIGURE IV-3B) alone also flattens 
its effect by a mechanism that is unknown but may involve induction of 11β-HSD2. 
Adding 6β-hydroxycorticosterone then restores corticosterone’s effect, possibly by 
inhibiting 11β-HSD2 activity and/or expression (FIGURE IV-7, FIGURE IV-8, and 
FIGURE IV-9). 
FIGURE IV-3. Interaction between GR and MR blockade and 6β-
hydroxycorticosterone effects on ENaCα mRNA induction by corticosterone.  
A: Cells were treated for 24 h with varying concentrations of B and 10-5 M RU486 
(R), 10-5 M 6β-OHB (6b), or both. B: Varying concentrations of B and 10-5 M 
spironolactone (S), 10-5 M 6β-OHB, or both. 
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6β-OHB suppresses ALDO response: Cells were treated with increasing 
concentrations of aldosterone (ALDO) for 24 hours with and without the addition of 
10-5 M 6β-hydroxycorticosterone. The expected increase of ENaCα mRNA in 
response to aldosterone was dampened significantly when 6β-hydroxycorticosterone 
was added (FIGURE IV-4). 
 
 
 
 
 
 
 
 
 
 
FIGURE IV-4. ENaCα mRNA dose-response with or without 10-5 M 6β-
hydroxycorticosterone.  
mIMCD-K2 cells dose-dependently increase ENaCα mRNA levels at 24 h in 
response to ALDO treatment, but 10-5 M 6β-OHB significantly blunts this response. 
 
mIMCD-K2 cells convert corticosterone: Cells were incubated with 2 nM [3H]-
corticosterone and 100 nM unlabeled corticosterone for the time-points indicated in 
FIGURE IV-5A, which shows a time-dependent increase in corticosterone 
conversion. A decrease in the apparent ratio of 11-dehydrocorticosterone to 
corticosterone at longer time-points (not shown) may represent the action of 11β-
HSD1. Therefore, 30-min incubations were performed for substrate-velocity and 
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inhibition experiments. In order to establish that corticosterone conversion reflected 
11β-HSD2 activity, cell homogenates were assayed with and without the addition of 
1mM NAD+ (an 11β-HSD2 cofactor) and 100 nM Ca2+ (an 11β-HSD2 inhibitor), as 
shown in FIGURE IV-5B. Conversion was stimulated by NAD+ and inhibited by Ca2+, 
which is consistent with 11β-HSD2 activity (195). 
 
 
 
 
 
 
 
 
FIGURE IV-5. Corticosterone conversion by mIMCD-K2 cells.  
A. Conversion is time-dependent. Separate assays showed an apparent decrease in 
the ratio of 11-dhB to B at longer time points (90-120 min). B. 1-hr B conversion is 
stimulated by NAD+ and inhibited by Ca2+, consistent with 11β-HSD2 activity. 
 
 
11β-HSD2 kinetics: Data from 30-min incubations of cells with 2 nM [3H]-
corticosterone and varying unlabeled corticosterone concentrations were fitted by 
nonlinear regression, assuming Michaelis-Menten kinetics. The substrate-velocity 
curve is shown in FIGURE IV-6. The estimated Michaelis-Menten constant (Km) for 
these data is roughly 150 nM (SE= 35 nM). 
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FIGURE IV-6. Whole-cell 11β-HSD2 substrate-velocity curve.  
Cells were incubated for 30 min with 2 nM [3H]-B and varying concentrations of 
unlabeled B. 
 
6β-hydroxycorticosterone inhibits corticosterone conversion: Cells were 
incubated for 30 min with 2 nM [3H]-corticosterone and indicated corticosterone and 
6β-hydroxycorticosterone concentrations to test the hypothesis that 6β-
hydroxycorticosterone competitively inhibits 11β-HSD2 activity (FIGURE IV-7A). 
Substrate-velocity and double-reciprocal plots (inset) are shown. The best-fit 
estimate for the inhibitory constant (KI) for these data is 4.7 nM (SE= 2.3). The 
relative abilities of corticosterone and 6β-hydroxycorticosterone to inhibit the 30-min 
conversion of 2 nM [3H]-B was also examined (FIGURE IV-7B). At all concentrations, 
6β-hydroxycorticosterone produced greater inhibition than did corticosterone. 
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FIGURE IV-7. 6β-hydroxycorticosterone inhibits 11β-HSD2 activity. 
Cells were incubated for 30 min with 2 nM [3H]-B and with the indicated 
concentrations of unlabeled B or of 6β-OHB. A. Substrate-inhibitor profile. Estimated 
Ki=4.7 nM. B. B and 6β-OHB dose-dependently inhibit [3H]-B conversion. 
 
6β-hydroxycorticosterone suppresses 11β–HSD2 mRNA and activity: Cells 
were cultured in 10-7 M corticosterone +/- 10-5 M 6β-hydroxycorticosterone. By 2 h, 
corticosterone had suppressed by half the mean 11β–HSD2 mRNA level (FIGURE 
IV-8A), which recovered from 2-8 h in the absence of 6β-hydroxycorticosterone; in 
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its presence, recovery was flat. In separate studies, the time- and dose-dependence 
of this effect were examined for 11β–HSD1 and 2 (FIGURE IV-8B and C). With 
corticosterone alone, HSD1 mRNA levels decreased from 4 to 8 h while 11β–HSD2 
levels increased. 6β-hydroxycorticosterone dose-effect trends on 11β–HSD1 at 2 
and 4 h were marginal in significance (P=0.04 and 0.09, respectively). At 8h, only 
the trend for 11β–HSD2 was significant (P=0.001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE IV-8. 6β-hydroxycorticosterone affects 11β-HSD mRNA levels.  
Cells were incubated up to 8h with 10-7 M B and the indicated concentrations of 6β-
OHB. A. 6β-OHB reduces 11β-HSD2 mRNA recovery after suppression by B. B and 
C. 6β-OHB dose-dependently inhibit [3H]-B conversion; 6β-OHB was more potent 
than B at all doses. 
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Culturing mIMCD-K2 cells for 24 h in 10-7 M corticosterone alone or with the 
11β–HSD2 inhibitor carbenoxolone (10-5 M) or 6β-hydroxycorticosterone (10-6 or 10-5 
M) suppressed 11β–HSD2 activity (FIGURE IV-9). 
 
 
 
 
 
 
 
 
FIGURE IV-9. 6β-hydroxycorticosterone suppresses 11β-HSD2 activity.  
Cells were incubated for 24 h with 10-7 M B and the indicated concentrations of CBX 
and 6β-OHB. 10-5 M 6β-OHB suppressed 11β-HSD2 activity. 
 
DISCUSSION 
The primary purpose of these experiments was to determine whether 6β-
hydroxycorticosterone, a product of CYP3A-catalyzed metabolism, alters renal 
sodium transport by changing the expression of ENaC subunits. The secondary 
purpose was to identify potential mechanisms and to specifically test the hypothesis 
that 6β-hydroxycorticosterone inhibits the 11β-HSD2 enzyme. Cultured mouse inner 
medullary collecting duct cells have been used previously as in vitro models of 
steroid regulation of sodium transport.  
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The major findings of these experiments are that 6β-hydroxycorticosterone 
competitively inhibits 11β-HSD2 activity and that it has an unanticipated effect upon 
11β-HSD2 expression. 6β-hydroxycorticosterone inhibition of 11β-HSD2 activity 
appears to occur in a physiologically compatible range. Results from whole-cell 
enzyme assays indicate that corticosterone conversion is consistent with Michaelis-
Menten kinetics. The estimated Km, roughly 150 nM, is higher than published Km 
values for 11β-HSD2, which range from 10-100 nM. It is not clear whether this 
difference is meaningful, but the presence of 11β-HSD1 in these cells may be 
responsible for a higher apparent Km due to back-conversion of product to substrate. 
The derived Ki for 6β-hydroxycorticosterone in this reaction is around 5 nM.  
Data regarding the intracellular levels of 6β-hydroxyglucocorticoids are not 
available from the literature. Human plasma 6β-hydroxycortisol levels average 1-3 
nM but are higher in hypercortisolemic states, in which they may exceed 10 nM, and 
in tissues in which 6β-hydroxycortisol is produced, such as the adrenal gland (129, 
149). The levels of 6β-hydroxycortisol in the urine can reach the micromolar range, 
which may indicate high intrarenal concentrations. It is very likely that the ratio of 6β-
hydroxycortisol to cortisol in renal epithelial cells exceeds that in plasma. The efflux 
transporter P-glycoprotein (P-gp), encoded by the MDR1 gene, limits the intracellular 
concentrations of its steroid ligands, including glucocorticoids (117, 196-198). 
Steroid transport by P-gp is sensitive to structural and physicochemical properties of 
these compounds. Introduction of a 6β-hydroxyl group to cortisol greatly reduces 
transport by LLC-PK porcine kidney cells with or without transfection with MDR1 
(199). The in vivo relevance of this finding would be that the intracellular ratio of 6β-
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hydroxycortisol to cortisol may be higher than that seen in plasma, as cortisol is 
pumped out of the cell and 6β-hydroxycortisol formed intracellularly by CYP3A is 
cleared less efficiently. 
CYP3A11 expression was not reliably seen in these cells. CYP3A11 mRNA is 
detectable in adult mouse kidney, although at relatively low levels compared to 
CYPs from families 1, 2, and 4 (200).  CYP3A5 expression in medullary collecting 
ducts has been confirmed in humans (84). In future studies, it will be worth asking 
what the effects of actual CYP3A expression would be in these cells. 
The higher relative mRNA levels for GR relative to those for MR in these cells 
parallel a GR predominance previously noted in cultured collecting duct cells (126). 
The higher relative mRNA levels for 11β-HSD1 relative to those for 11β-HSD2 are 
consistent with results from other investigators showing 11β-HSD1 in rat distal 
tubules (201) and higher TaqMan and Western blot signals for 11β-HSD1 than for 
11β-HSD2 in the inner medulla (202). 
The in vivo relevance of these findings is unclear. Inhibition of 11β-HSD2 
should in theory have an antinatriuretic effect. But the apparent ability of 6β-OHB to 
antagonize the MR and the possible dependence of 6β-hydroxycorticosterone 
effects on MR or GR blockade makes the proposed role of 6β-hydroxycorticosterone 
in normal renal and systemic physiology somewhat difficult to predict. Further in vitro 
and in vivo studies should detail more finely define the dose effects of 6β-
hydroxycorticosterone and explore its effects on not merely ENaC mRNA but also 
levels and activities of other effectors of sodium balance, such as Na+/K+-ATPase, 
Na+/K+/Cl- cotransporter (NKCC), and renin-angiotensin-aldosterone system 
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components. But whether or not 6β-OHB proves to be a major agent in human 
physiology and health, studies of its effects should provide new insights into the 
biology of renal epithelia. 
 
  
 
 
 
CHAPTER V: IN VIVO MODELS OF CYP3A PHYSIOLOGY 
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SUMMARY 
Animal and human data suggest that high CYP3A activity in the kidney may cause 
increased renal sodium transport. Cytochrome P450 3A enzymes have been 
proposed to alter renal sodium reabsorption by catalyzing the conversion of 
glucocorticoids (cortisol or corticosterone) to their 6β-hydroxylated metabolites with 
altered activity. The mechanisms by which these metabolites act in the kidney have 
not previously been identified. Excessive reabsorption of sodium by the kidney may 
cause increased plasma volume and a resultant hypertension. Previous studies of a 
possible relationship between CYP3A activity and blood pressure and/or renal 
function have been mostly associative, without establishing clear causation. These 
studies are an attempt to establish whether increased 6β-hydroxycorticosterone 
levels and or increased expression of CYP3A enzymes in mice can increase sodium 
sensitivity and/or blood pressure. 
 
INTRODUCTION 
The search for genetic causes of common diseases such as hypertension is difficult 
because disease-causing genetic variants are generally either rare or have little 
effect individually. It has been suggested that the cytochrome P450 3A (CYP3A) 
enzyme system could have large effects on human health. Among adults, CYP3A4 
and CYP3A5 exhibit variable expression which is partly controlled by genetic 
variance. CYP3A4 is variably but universally expressed primarily in the liver and 
intestines; CYP3A5 is found in the gastrointestinal system and in the renal epithelia 
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of some individuals who constitute a minority among some populations and a 
majority among others. The large active sites of CYP3A enzymes allow them to 
catalyze the oxidative metabolism of a wide variety of endogenous and exogenous 
chemicals, including most therapeutic drugs.  
The work of Watlington and colleagues implicated CYP3A enzymes in the 
control of renal sodium balance and blood pressure. CYP3A content and catalytic 
activity in the kidneys of spontaneously hypertensive rats (SHR) are higher than in 
normotensive Wistar-Kyoto rats (80, 85) and treatment of SHR with the CYP3A 
inhibitor troleandomycin lowers BP (85). Several human diseases associated with 
elevated BP, including Cushing’s syndrome (129) and pre-eclampsia (80), are 
characterized by increased urinary excretion of 6β-hydroxycortisol, a marker of in 
vivo CYP3A activity (85, 130). Plasma levels of 6β-hydroxycortisol have been 
reported to be elevated in essential hypertensives (87) 
A role for CYP3A enzymes in blood pressure control appears plausible. 
CYP3A-mediated 6β-hydroxylation is a metabolic pathway, although a minor one, for 
steroids such as the glucocorticoid corticosterone. 6β-hydroxycorticosterone 
stimulates sodium transport across A6 toad kidney cells and sodium retention in rats 
(80-82). Previous evidence indicates that 6β-hydroxycorticosterone modulation of A6 
cell sodium transport by acting through an unidentified binding site (80, 81). 
Immunohistochemistry demonstrates CYP3A proteins in rat (80, 131) and human 
kidney (84), including the distal tubules and collecting ducts, the principle sites at 
which aldosterone stimulates sodium reabsorption. Similar to that of 11β-
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hydroxysteroid dehydrogenase type 2, renal CYP3A activity has been proposed to 
regulate glucocorticoid occupancy of the mineralocorticoid receptor (MR) (83). 
In addition, work by a number of investigators has indicated possible 
associations between CYP3A expression and blood pressure or sodium balance in 
some human studies. In order to move beyond association and establish causation, 
it will likely be necessary to employ animal models so that the effects of modulating 
CYP3A activity upon in vivo physiology can be measured.  
 
METHODS 
6β-hydroxycorticosterone injection: Wild-type C57BL/6 male mice were 
separated into two groups (n=4 each) that received a daily intraperitoneal injection of 
either 6β-hydroxycorticosterone (1 µg/g body weight) in PBS or with PBS alone. 
Each group received a normal-chow diet and drinking water ad libitum. Blood 
pressures were measured daily for 6 days. Drinking water was then replaced with 
0.9% saline, injections were continued, and blood pressure measurements were 
repeated for an additional 6 days. 
 
PGK-CYP3A5 tg mice: Functional human CYP3A5 cDNA in a pENTR/SD/DTOPO 
cloning vector (Invitrogen) was kindly provided by the laboratory of Erin Schuetz (St. 
Jude’s Children’s Research Hospital, Memphis, TN). CYP3A5 cDNA was excised 
from the pENTR vector and ligated into a transgenic vector directed by a 
phosphoglycerate kinase (PGK) promoter (UNC Animal Models Core). The vector 
was linearized and microinjected into male pro-nuclei of fertilized C57BL/6 oocytes 
87 
by standard techniques. Founders were identified by PCR of tail or toe DNA using 
primers that anneal within the PGK promoter (AGCAGTGCATCTGGGGGCAG; 
forward) and CYP3A5 cDNA (GGAGTTGACCTTCATACGTTCCCCAC; reverse). 
Founders were mated with wild-type C57BL/6 in order to produce transgenic and 
wild-type offspring. 
 
ApoAI-ApoCIII-CYP3A5 mice: Human CYP3A5 cDNA was ligated into a targeting 
construct containing mouse apoA1 gene and a 3’ fragment of the apoC3 gene (203). 
Inserting a transgene into this locus produces high expression of the transgene in 
the liver and intestines (204). Chimeric males were mated with wild-type C57BL/6 
females. Transgenic and wild-type agouti F1 offspring were used for experiments. 
Genotyping of ApoCYP3A5 mice was performed by PCR amplification of tail or toe 
DNA using oligonucleotide primers that anneal within the PGK promoter and 
CYP3A5 cDNA, as for PGK-CYP3A5 mice. 
 
Blood Pressure Measurement: Noninvasive computerized tail cuff 
sphygmomanometry was used for BP measurements of conscious mice. Each trial 
consisted of six consecutive days of measurements. On each day, a series of 10 
inflations is performed to allow the mouse to acclimatize to the apparatus, after 
which 30 inflations and measurements were performed. The average of the six daily 
means was used to represent the mean blood pressure of each animal and is used 
for statistical analysis. 
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Diets: PGK-CYP3A5 were fed either normal chow, a high-salt diet (8% sodium), and 
a low-salt diet (1% sodium). ApoCYP3A5-transgenic and wild-type mice were 
crossed over between normal chow, a high-salt diet (8% sodium), and a high-fat diet 
(42% of calories from fat). All diets were from Harlan-Teklad. Mice were allowed to 
acclimate to each diet for one week prior to each 6-day round of blood pressure 
measurement. 
 
RESULTS 
6β-hydroxycorticosterone injection did not influence sodium sensitivity: 
Ingestion of saline non-significantly increased systolic and diastolic blood pressure 
and lowered heart rate among 6β-hydroxycorticosterone- and PBS-treated mice. 
Injection with 6β-hydroxycorticosterone as opposed to PBS did not significantly 
affect these responses. Also, 6β-hydroxycorticosterone did not exhibit a BP-raising 
effect and nonsignificantly lowered SBP and raised HR (FIGURE V-1). 
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FIGURE V-1. 6β-hydroxycorticosterone affects blood pressure and heart rate. 
 
Effects of CYP3A5 gene introduction on blood pressure: PGK-CYP3A5 
transgenic demonstrated expression of CYP3A5 mRNA in the liver and kidney and 
suppression of endogenous mouse CYP3A11 in these same tissues (FIGURE V-2). 
Renal CYP3A11 expression was 1000-fold lower than hepatic expression for both 
wild-type and transgenic mice. These mice showed trends towards higher systolic 
(SBP) and diastolic blood pressures (DBP) on low- (LS) and high-salt (HS) diets. 
Mean SBP and DBP were nearly equal between transgenic and wild-type mice on a 
normal-salt (NS) diet (FIGURE V-3). Among the ApoAI/CIII-CYP3A5 mice there was 
no apparent genotype effect on blood pressure but there was a diet effect among 
H2O 
NaCl 
90 
wild-type and CYP3A5-positive mice such that high-fat diet lowered blood pressure 
(FIGURE V-4). 
 
 
 
 
 
 
 
 
FIGURE V-2. Relative hepatic and renal expression of CYP3A11 mRNA in wild-
type and PGK-CYP3A5 transgenic mice. 
 
 
 
 
 
 
 
FIGURE V-3. Diet and PGK-CYP3A5 genotype effects on systolic and diastolic 
blood pressure. 
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FIGURE V-4. Dietary effects on systolic blood pressure and heart rate in 
ApoAI/CII-CYP3A5 transgenic and wild-type mice. 
Mice were fed normal chow (NC), high-salt (HS), or high-fat (HF) diet. Bars show 
means and standard deviations of systolic blood pressure (SBP) and heart rate 
(HR). 
 
DISCUSSION 
The multiple CYP3A genes in humans, mice, and other animals reflect species-
specific gene duplication and recombination events. There is thus no clear mouse 
ortholog of the human CYP3A5 gene, although the mouse and human CYP3A 
genes are obviously homologous. The attempt to create a mouse model that 
perfectly replicates the in vivo distribution and activity of human CYP3A5 is difficult 
in theory. In this study, it was attempted to circumvent the potential problems of 
achieving the proper tissue-specific distributions of “CYP3A5-like” activity by 
employing multiple approaches to model the potential hypertensive effects of CYP3A 
and/or 6β-hydroxycorticosterone activity.  
CYP3A7 transgenic mice with a metallothionein promoter driving zinc-induced 
hepatic expression have previously been made (205, 206). These animals show 
increased serum testosterone levels, higher liver, kidney, and uterine weights, and 
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decreased testis weight. The reasons for these effects were not studied but 
testicular expression of CYP3A7 was confirmed. The authors speculated that the 
higher testosterone in conjunction with smaller testes may have reflected transgene 
disruption of a gene responsible for testosterone metabolism, such as the gene 
encoding steroid 5α-reductase. It is more likely, however, that products of testicular 
CYP3A-catalyzed reactions, such as 6β-hydroxytestosterone, alter activity or 
expression of 5α-reductase or a related enzyme. Physiologic parameters, such as 
blood pressure, have not been reported for other humanized CYP3A models as they 
have for the models described in this chapter. 
  Repression of endogenous mouse CYP3A mRNA was not seen in the 
CYP3A7-transgenic model (207). But a 50% reduction of mouse hepatic CYP3A 
protein levels was observed in female mice bearing a CYP3A4 transgene driven by 
the full CYP3A4 promoter; transgenic males showed an age-dependent increase in 
murine hepatic CYP3A protein levels that exceeded those of wild-type males by 12 
weeks of age (208). Mechanisms underlying these effects and differences between 
models have not been explained. 
 The possible effects of 6β-hydroxycorticosterone on blood pressure and heart 
rate at baseline and in response to dietary sodium modification may be further 
investigated in intact and adrenalectomized mice. Doses of 6β-
hydroxycorticosterone may be varied in the presence or absence of 11β-HSD2 
inhibition (with carbenoxolone or glycyrrhetinic acid), and antagonism of the 
mineralocorticoid or glucocorticoid receptors (with spironolactone or RU486, 
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respectively). It will be informative to measure not only hemodynamic parameters 
but also indicators of renal function and sodium balance. 
 It is similarly necessary to investigate the possible effects of PGK-CYP3A5 
transgenesis on hemodynamics and renal function. It will be informative to compare 
the magnitude and distribution of CYP3A expression and activity between wild-type 
and transgenic animals. 
 
 
 
 
 
 
 
 
  
 
 
 
 
CHAPTER VI: SYSTEMATIC REVIEW OF STUDIES OF THE ASSOCIATION OF 
CYP3A5 GENOTYPE WITH BLOOD PRESSURE AND HYPERTENSION 
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SUMMARY 
 Isoforms of the human CYP3A subfamily are well known as hepatic drug-
metabolizing enzymes. Beyond their pharmacologic importance, CYP3A enzymes 
have established and hypothesized roles in endogenous physiologic processes. In 
animal and in vitro models, 6β-hydroxycorticosterone, a product of CYP3A enzyme 
activity, increases renal sodium transport and is associated with increased blood 
pressure. Among humans, increased plasma levels and urinary excretion of 6β-
hydroxycortisol have been seen in diseases associated with increased blood 
pressure. Polymorphic human renal CYP3A activity primarily reflects the 
contributions of CYP3A5, the expression of which is primarily controlled by known 
single nucleotide polymorphisms. These observations led to the hypothesis that 
expression-predicting CYP3A5 genotypes could predict renal sodium transport and 
blood pressure. Studies have examined associations between the CYP3A5 A6986G 
SNP and blood pressure, hypertension, renal function, and other metabolic 
phenotypes among American and African blacks, American and European whites, 
and various Asian groups. A review of studies to date shows that results have been 
quite variable. Summary measures show very minor and insignificant associations of 
CYP3A5 genotype with BP and HTN among whites, possible associations among 
Asians, and variable results among blacks. These observations support the notion 
that development of robust, conventional molecular epidemiologic case-control 
studies to address these questions, including gene-gene and gene-environment 
interactions, will be timely.  
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INTRODUCTION 
The cytochrome P450 (CYP) enzyme superfamily is an exceptionally diverse group 
divided into roughly 237 numbered families on the basis of sequence homology (1, 
2). CYP1-3 families comprise the phase I drug-metabolizing enzymes (4), which 
catalyze substrate functionalization via reactions such as hydroxylation and 
demethylation that increase aqueous solubility or introduce attachment sites for 
bulkier moieties added by phase II enzymes. CYP proteins are expressed in the liver 
and throughout the gastrointestinal tract, where the bulk of first-pass drug 
metabolism occurs (5).  
The human CYP3A enzymes- i.e., the members of family 3, subfamily A of 
the CYP superfamily- are numbered 4, 5, 7, and 43. The CYP3A isoforms have 
extensively overlapping substrate specificities. Among the human CYP subfamilies, 
CYP3A is the most prominent. Its members are the most highly expressed in the 
liver and intestines and they catalyze metabolism of a tremendous variety of 
substrates, including half or more of currently marketed drugs (9). The bulk of adult 
human CYP3A activity results from the contributions of the CYP3A4 and CYP3A5 
enzymes. 
Gastrointestinal CYP3A4 activity is variable but universal (209, 210). But 
CYP3A5 expression is clearly polymorphic (25, 42). Among individuals who express 
CYP3A5, it is the primary component of extrahepatic CYP3A activity. While CYP3A4 
and 5 may be co-expressed in extra-gastrointestinal sites such as the placenta (27), 
CYP3A5 is also found in sites from which CYP3A4 absent- i.e., the kidney (28-30), 
including proximal and distal tubules and collecting ducts (21, 31); adrenal zona 
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glomerulosa (21, 31); bronchial and alveolar respiratory epithelia (32); and anterior 
pituitary gland (33). 
The human CYP3A5 gene is located on band q22.1 of chromosome 7. The 
CYP3A5 gene encompasses roughly 31.8 kbp and has 13 exons. The CYP3A5 
promoter contains a basal transcription element (–35 to –50), binding sites for AP-3 
and p53. The CYP3A5 5’UTR displays response elements for the pregnane X 
receptor (PXR), the main effector of CYP3A transcriptional induction (211). Also 
found in the CYP3A5 promoter are glucocorticoid and estrogen response elements 
and hepatocyte nuclear factor-4 and -5 binding sites (212). The CYP3A5 holoprotein 
consists of 502 amino acids with a molecular weight of 57.1 kDa. 
In addition to their roles in the metabolism of drugs and other exogenous 
chemicals, CYP3A enzymes also constitute a significant metabolic pathway for 
lipophilic endogenous molecules, as reviewed in Chapter I. The risk for diseases and 
conditions such as breast and prostate cancer and early puberty (153, 154, 157, 
161) have been hypothesized to be modulated by CYP3A-mediated transformation 
of estrogens and androgens. Most relevant to this review is the specific status of 
CYP3A enzymes, and especially CYP3A5, as glucocorticoid 6β-hydroxylases. 
CYP3A5 is an attractive candidate as a gene influencing hypertension. 
Hydroxysteroid products of CYP3A-catalyzed reactions modulate sodium transport 
across cultured toad kidney cells. CYP3A enzymes are expressed in rodent and 
human renal tubules, including the distal tubules and collecting ducts, the major sites 
at which mineralocorticoids control renal sodium reabsorption. CYP3A enzymes are 
overexpressed in the kidneys of the spontaneously hypertensive rat (SHR) relative 
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to the related normotensive Wistar-Kyoto strain, and treatment of SHR with a 
CYP3A inhibitor reduces blood pressure. Injection of SHR with 6β-
hydroxycorticosterone leads to sodium retention. Excess urinary 6β-hydroxycortisol 
excretion has been noted in diseases marked by increased blood pressure, such as 
Cushing’s syndrome and pre-eclampsia. The response of urinary 6β-hydroxycortisol 
excretion to sodium loading has been reported to differ between individuals whose 
blood pressure is sodium-sensitive and those who are sodium-resistant. A study of 
essential hypertensives revealed higher plasma 6β-hydroxycortisol levels among 
hypertensives than among normotensives. The observation that the probability of 
CYP3A5 expression followed a roughly equatorial-to-polar gradient suggested the 
possibility that the evolutionary importance of renal CYP3A5 activity may have been 
an ability to prevent dehydration by enhancing sodium resorption. This hypothetical 
antinatriuretic effect was proposed to lead to increased blood pressure in situations 
in which sodium availability exceeds requirements, as in the modern Western diet. 
Perhaps fittingly, CYP3A5 expression is most frequently observed among African-
Americans and Black Africans, among whom global rates of hypertension and 
sodium sensitivity are the highest (123, 124). The possibility that CYP3A5 was a 
“hypertension gene” was also intriguing because of CYP3A5’s activity as a drug 
metabolizing enzyme, thus presenting CYP3A5 as a possible “double effector” that 
could control both the likelihood of developing hypertension and the likelihood of 
responding to antihypertensive treatment. 
The 2001 report by Kuehl et al. (25) of the major genetic variant (A6986G) 
underlying polymorphic CYP3A5 expression enabled the development of studies 
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associating CYP3A5 expression with a variety of pharmacologic and physiologic 
phenotypes. Thus, Givens et al. (30) examined the association of the CYP3A5 
A6986G SNP with blood pressure and other clinical findings among a small group of 
young, mostly college-aged, healthy African-Americans who had been screened for 
a pharmacogenetic study. Significant associations with CYP3A5 genotype were 
noted for systolic blood pressure and creatinine clearance. Subsequent studies by 
others investigating CYP3A5 genotype association with blood pressure and/or the 
diagnosis of hypertension have produced variable results. This review is an attempt 
to quantitatively and qualitatively review the current data and assess the state of the 
evidence. Significant variability exists among studies in terms of subject selection, 
methodology, and results. Future analyses of this type require more standardized 
reporting of subject characteristics. 
 
METHODS 
ISI Web of Science, Medline, CINAHL, and EMBASE were searched for all articles 
and abstracts mentioning both CYP3A5 and blood pressure or both CYP3A5 and 
hypertension. Materials that did not include an association of CYP3A5 genotype and 
blood pressure or hypertension as a primary or secondary analysis were removed.  
 
Statistical analyses: For studies included in the meta-analysis, the main outcome 
measures extracted were systolic blood pressure and the proportion of 
hypertensives among CYP3A5 expressers and nonexpressers. For the purpose of 
pooled analyses, statistics that could be used to estimate the variances of the 
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outcome measures were also recorded. These included standard deviations or 
standard errors, or if these statistics were not given, confidence intervals or exact t 
or P values. For studies of systolic blood pressure, the mean difference between the 
CYP3A5 expresser and nonexpresser groups and the pooled standard deviation 
were used to calculate a z score. For hypertension, z scores were calculated from 
odds ratio of hypertension among expressers versus nonexpressers. It was 
assumed that genotype effects were not different between males and females, so 
data from studies reporting data for males and females separately were transformed 
by standard methods. Mean effect sizes were calculated by weighting each trial by 
the inverse of the variance. Funnel plot asymmetry was used to detect publication 
biases among the studies. 
 
RESULTS 
Fifteen publications were identified comprising 10,859 subjects. Relevant summary 
data, including means and measures of variation, were extracted from each study. 
The list of identified studies is displayed in TABLE VI-A. For meta-analysis, studies 
that examined healthy subjects were included. Data from suitable studies were 
entered into MIX (Meta-analysis with Interactive Explanations), a freely-available and 
user-friendly software (213). MIX was used for all analyses.  
 A random effects model was used to take into account inter-study 
heterogeneity. Publication bias was unapparent on the basis of funnel plots. Forest 
plots and summary measures for systolic blood pressure and hypertension among 
all subjects, healthy Whites, healthy Blacks, and healthy Asians were generated. 
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The summary estimate for CYP3A5 genotype effect among all subjects was a 0.29-
mm Hg increase (P= 0.41) in systolic blood pressure among CYP3A5*1 non-carriers 
(FIGURE VI-1). Sizable or significant effects of genotype upon systolic blood 
pressure or hypertension among any group were unapparent among all subgroups. 
 
FIGURE VI-1. Forest plot of studies associating systolic blood pressure with 
CYP3A5 genotype. 
 
DISCUSSION 
The absence of an apparent effect of CYP3A5 genotype on blood pressure or 
hypertension may indicate that in reality no true effect exists, or that any actual effect 
is swamped by other genetic and environmental variables, or that studies have been 
too varied in methodology to allow for adequate statistical summation. The results of 
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this meta-analysis might be considered alongside those of a recent meta-analysis of 
genetic association studies of the M235T angiotensinogen polymorphism. Despite a 
clear role for angiotensinogen in the control of BP and the ability of M235T to predict 
angiotensinogen plasma levels, meta-analysis demonstrates unconvincing evidence 
for M235T as a predictor of blood pressure or the risk of hypertension (214). 
While more than 10,000 subjects have been included in published CYP3A5-
blood pressure association studies, only about 800 of these subjects are classified 
as black or African-American, African, or of African descent. For various reasons, 
this figure may represent a significant underrepresentation of the subjects most likely 
to exhibit a CYP3A5 effect. Rigorous study of a role for CYP3A5 in blood pressure 
and related parameters is likely to require greater recruitment of black subjects. 
 Because of heterogeneity among studies, this analysis is presented only as 
an assessment of the state of the evidence, not as a definitive conclusion about the 
effects of CYP3A5 genotype. The results support the notion that development of 
robust, conventional molecular epidemiologic case-control studies to address these 
questions, including gene-gene and gene-environment interactions, will be helpful. 
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 TABLE VI-A. Studies of CYP3A5 genotype and blood pressure or 
hypertension 
N 
 
Study 
Popu-       
lation(s) *1/*1 *1/X X/X Total Major Findings 
Givens et al. 
2003 (30) 
AA 9 9 7 25 *1 allele associates with 
higher SBP, PP, CrCl. 
Kreutz et al. 
2005 (169) 
CA 
(Dutch) 
43 858 5876 6777 *1 allele associates with 
lower SBP, PP, and UNa 
among women. 
Fromm et al. 
(164) 
CA 
(German) 
0 19 96 115 *1/*3 genotype associates 
with lower SBP, higher 
serum ALDO. 
Ho et al. 2005 
(165) 
     Study 1 
   
 
CA 
AA 
 
0 
27 
 
29 
39 
 
170 
6 
 
199 
72 
*1 allele associates with 
HTN among AA. 
     Study 2 CA 
AA 
1 
72 
34 
78 
204 
23 
239 
173 
*1 allele associates with 
higher insulin resistance 
among CA. 
Kreutz et al. 
2004 (170) 
Renal Tx: 
Recipient 
Donors 
 
6 
5 
 
56 
42 
 
337 
352 
 
399 
399 
No association of *1 allele 
with BP. 
Kivisto et al. 
2005 (168) 
CA 
(Finnish, 
age ≥75) 
0 
 
55 
 
318 
 
373 
 
*1 allele associates with 
HTN; MDR1 3435C>T 
does not. 
Bochud et al. 
2006, 2007 
(54, 162) 
East 
African 
67 194 114 375 *1 allele predicted age-
dependent increase in 
daytime SBP, DBP. Renal 
Na reabsorption decreased 
by age in nonexpressers 
but in expressers. 
Yin et al. 
2006  
Chinese 7 35 51 93 Nonsignificant associations 
between 6986 genotype 
and SBP, DBP, HR, and 
CrCL. 
Lieb et al. 
2004 (172) 
CA 
(German) 
 
5 115 964 1084 No genotype association 
with BP, left ventricular 
mass or geometry. Mild 
association with eGFR. 
Neville et al. 
2005; 
Marunde et 
al. 2006 
Nigerian 
males 
35 55 16 106 No genotype association 
with SBP, DBP, BMI. 
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Jin et al. Japanese 
males 
0 8 8 16 7-mm Hg-higher SBP 
among *1/*3 vs. *3/*3 
Suh et al. 
2006 (215) 
Korean 
cardiac 
patients 
33 122 193 348 No significant differences 
in rates of HTN or DM. 
Kim et al. 
2006 (216) 
Korean 
males 
2 16 24 40 No association of *1 with 
SBP, DBP, or HR. 
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